<SEC-DOCUMENT>0001193125-26-077416.txt : 20260226
<SEC-HEADER>0001193125-26-077416.hdr.sgml : 20260226
<ACCEPTANCE-DATETIME>20260226172020
ACCESSION NUMBER:		0001193125-26-077416
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20260225
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260226
DATE AS OF CHANGE:		20260226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vir Biotechnology, Inc.
		CENTRAL INDEX KEY:			0001706431
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				812730369
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39083
		FILM NUMBER:		26690589

	BUSINESS ADDRESS:	
		STREET 1:		1800 OWENS STREET
		STREET 2:		SUITE 900
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-906-4324

	MAIL ADDRESS:	
		STREET 1:		1800 OWENS STREET
		STREET 2:		SUITE 900
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d85338d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vir="http://www.vir.bio/20260225" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-288">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2026-02-25_to_2026-02-25">0001706431</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="vir-20260225.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2026-02-25_to_2026-02-25"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-02-25</xbrli:startDate> <xbrli:endDate>2026-02-25</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-299">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2026-02-25_to_2026-02-25" format="ixt:datemonthdayyearen" id="ixv-300">February&#160;25, 2026</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-301">Vir Biotechnology, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2026-02-25_to_2026-02-25" format="ixt-sec:stateprovnameen" id="ixv-302">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-303">001-39083</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-304">81-2730369</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(State or Other Jurisdiction<br/>of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(IRS Employer<br/>Identification No.)</span></td></tr></table> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-305">1800 Owens Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-306">Suite 900</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-307">San Francisco</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2026-02-25_to_2026-02-25" format="ixt-sec:stateprovnameen" id="ixv-308">California</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-309">94158</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-310">(415)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-311">906-4324</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2026-02-25_to_2026-02-25" format="ixt-sec:boolballotbox" id="ixv-312">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2026-02-25_to_2026-02-25" format="ixt-sec:boolballotbox" id="ixv-313">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2026-02-25_to_2026-02-25" format="ixt-sec:boolballotbox" id="ixv-314">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2026-02-25_to_2026-02-25" format="ixt-sec:boolballotbox" id="ixv-315">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-316">Common stock, $0.0001 par value</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-317">VIR</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2026-02-25_to_2026-02-25" format="ixt-sec:exchnameen" id="ixv-318">Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#160;240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2026-02-25_to_2026-02-25" format="ixt-sec:boolballotbox" id="ixv-319">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;1.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;25, 2026, Vir Biotechnology, Inc. (Vir Bio) entered into an underwriting agreement (the Underwriting Agreement) with Goldman Sachs&#160;&amp; Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc., as representatives of the several underwriters named in Schedule I thereto (the Underwriters), in connection with the offer and sale by Vir Bio of 17,647,059&#160;shares of common stock of Vir Bio, par value $0.0001 per share (Common Stock), at a price to the public of $8.50 per share (the Offering). The Offering is expected to close on February&#160;27, 2026, subject to the satisfaction of customary closing conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Underwriting Agreement, Vir Bio granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 2,647,058 shares of Common Stock at the public offering price. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vir Bio expects to receive net proceeds from the Offering of approximately $141.1&#160;million, or approximately $162.3&#160;million if the Underwriters exercise in full their option to purchase additional shares, after deducting underwriting discounts and commissions and estimated Offering expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares are being offered and sold by means of an effective registration statement on Form <span style="white-space:nowrap">S-3ASR,</span> including a base prospectus, filed with the U.S. Securities and Exchange Commission on November&#160;3, 2023 (File <span style="white-space:nowrap">No.&#160;333-275314),</span> and a prospectus supplement dated February&#160;25, 2026. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement contains customary representations, warranties and covenants by Vir Bio, customary conditions to closing and indemnification obligations of Vir Bio and the Underwriters against certain liabilities. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates and were solely for the benefit of the parties to such agreement. The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to a copy of the Underwriting Agreement, which is filed herewith as Exhibit&#160;1.1 and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The legal opinion, including the related consent, of Gunderson Dettmer Stough Villeneuve Franklin&#160;&amp; Hachigian, LLP relating to the validity of the shares of the Common Stock in the Offering is filed as Exhibit 5.1 hereto. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:92%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8195;No.&#8195;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d85338dex11.htm">Underwriting Agreement dated as of February&#160;25, 2026, among Vir Biotechnology, Inc. and Goldman Sachs&#160;&amp; Co. LLC. Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc., as representatives of the underwriters named therein. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d85338dex51.htm">Opinion and Consent of Gunderson Dettmer Stough Villeneuve Franklin&#160;&amp; Hachigian, LLP. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d85338dex51.htm">Consent of Gunderson Dettmer Stough Villeneuve Franklin&#160;&amp; Hachigian, LLP (included in Exhibit&#160;5.1). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (formatted as inline XBRL)</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">VIR BIOTECHNOLOGY, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: February&#160;26, 2026</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Marianne De Backer</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Marianne De Backer, M.Sc., Ph.D., MBA</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Chief Executive Officer</p></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d85338dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Execution Version </I></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Vir Biotechnology, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:8%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Underwriting Agreement </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">February&nbsp;25, 2026 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp;
Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Barclays Capital Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As representatives (the
&#8220;Representatives&#8221;) of the several Underwriters </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">named in Schedule I hereto, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Goldman Sachs&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 West Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10282-2198 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Leerink Partners LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1301 Avenue of the Americas, 5th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10019 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Evercore Group L.L.C. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">55 East 52nd Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10055 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Barclays Capital Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">754 Seventh Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10019 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Vir Biotechnology, Inc.,
a Delaware corporation (the &#8220;Company&#8221;), proposes, subject to the terms and conditions stated in this agreement (this &#8220;Agreement&#8221;), to issue and sell to the underwriters named in Schedule I hereto (the
&#8220;Underwriters&#8221;) an aggregate of 17,647,059&nbsp;shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;, and such shares the &#8220;Firm&nbsp;Shares&#8221;) and, at the election of the
Underwriters, up to 2,647,058 additional shares (the &#8220;Optional Shares&#8221;) of Common Stock (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section&nbsp;2 hereof being collectively called the
&#8220;Shares&#8221;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. The Company represents and warrants to, and agrees with, each of the Underwriters that:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) An &#8220;automatic shelf registration statement&#8221; as defined under Rule 405 under the Securities Act of 1933, as amended (the
&#8220;Act&#8221;) on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-275314)</FONT> in respect of the Shares has been filed with the Securities and Exchange Commission (the
&#8220;Commission&#8221;) not earlier than three years prior to the date hereof; such registration statement, and any post-effective amendment thereto, became effective on filing; and no stop order suspending the effectiveness of such registration
statement or any part thereof has been issued and no proceeding for that purpose has been initiated or, to the Company&#8217;s knowledge, threatened by the Commission, and no notice of objection of the Commission to the use of such registration
statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Act has been received by the Company (the base prospectus filed as part of such registration statement, in the form in which it has most recently been filed with
the Commission on or prior to the date of this Agreement, is hereinafter called the &#8220;Base Prospectus&#8221;; any preliminary prospectus (including any preliminary prospectus supplement) relating to the Shares filed with the Commission pursuant
to Rule 424(b) under the Act is hereinafter called a &#8220;Preliminary Prospectus&#8221;; the various parts of such registration statement, including all exhibits thereto but excluding Form <FONT STYLE="white-space:nowrap">T-1</FONT> and including
any prospectus supplement relating to the Shares that is filed with the Commission and deemed by virtue of Rule 430B to be part of such registration statement, each as amended at the time such part of the registration statement became effective, are
hereinafter collectively called the &#8220;Registration Statement&#8221;; the Base Prospectus, as amended and supplemented immediately prior to the Applicable Time (as defined in Section&nbsp;1(c) hereof), is hereinafter called the &#8220;Pricing
Prospectus&#8221;; the form of the final prospectus relating to the Shares filed with the Commission pursuant to Rule 424(b) under the Act in accordance with Section&nbsp;5(a) hereof is hereinafter called the &#8220;Prospectus&#8221;; any reference
herein to the Base Prospectus, the Pricing Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form&nbsp;S 3 under the Act, as of the
date of such prospectus; any reference to any amendment or supplement to the Base Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any post-effective amendment to the Registration Statement, any
prospectus supplement relating to the Shares filed with the Commission pursuant to Rule 424(b) under the Act and any documents filed under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and incorporated therein, in
each case after the date of the Base Prospectus, such Preliminary Prospectus, or the Prospectus, as the case may be; any reference to any amendment to the Registration Statement shall be deemed to refer to and include any annual report of the
Company filed pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act after the effective date of the Registration Statement that is incorporated by reference in the Registration Statement; any oral or written communication with potential
investors undertaken in reliance on Rule 163B under the Act is hereinafter called a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#8220;Testing-the-Waters</FONT></FONT> Communication&#8221;; and any <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within the meaning of Rule 405 under the Act is hereinafter called a &#8220;Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication&#8221;; and any &#8220;issuer free writing prospectus&#8221; as defined in Rule 433 under the Act relating to the Shares is hereinafter called
an &#8220;Issuer Free Writing Prospectus&#8221;); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) (i) No order preventing or suspending the use of any Preliminary Prospectus or any
Issuer Free Writing Prospectus has been issued by the Commission, and (ii)&nbsp;each Preliminary Prospectus, at the time of filing thereof, conformed in all material respects to the requirements of the Act and the rules and regulations of the
Commission thereunder, and did not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were
made, not misleading; <I>provided</I>, <I>however</I>, that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with the Underwriter Information (as defined in Section&nbsp;9(b) of
this Agreement); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) For the purposes of this Agreement, the &#8220;Applicable Time&#8221; is 9:00 p.m.
(Eastern time) on the date of this Agreement. The Pricing Prospectus, as supplemented by the information listed on Schedule II(c) hereto, taken together (collectively, the &#8220;Pricing Disclosure Package&#8221;), as of the Applicable Time, did
not, and as of each<B> </B>Time of Delivery (as defined in Section&nbsp;4(a) of this Agreement) (as supplemented by any post-effective amendment thereto) will not, include any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; and each Issuer Free Writing Prospectus and each Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication does not conflict with the information contained in the Registration Statement, the Pricing Prospectus or the Prospectus and each Issuer
Free Writing Prospectus and each Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, as supplemented by and taken together with the Pricing Disclosure Package, as of the
Applicable Time, did not, and as of each<B> </B>Time of Delivery (as supplemented by any post-effective amendment thereto) will not, include any untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that this representation and warranty shall not apply to statements or omissions (i)&nbsp;made in reliance upon and in conformity
with the Underwriter Information or (ii)&nbsp;which are updated or supplemented by the Pricing Prospectus; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The documents incorporated
by reference in the Registration Statement, the Pricing Prospectus and the Prospectus, when they became effective or were filed with the Commission, as the case may be, conformed in all material respects to the requirements of the Act or the
Exchange Act, as applicable, and the rules and regulations of the Commission thereunder, and none of such documents contained an untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in
order to make the statements therein, in the light of the circumstances under which they were made, not misleading; any further documents so filed and incorporated by reference in the Registration Statement, the Pricing Prospectus and the Prospectus
or any further amendment or supplement thereto, when such documents become effective or are filed with the Commission, as the case may be, will conform in all material respects to the requirements of the Act or the Exchange Act, as applicable, and
the rules and regulations of the Commission thereunder and will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; provided,
however, that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with the Underwriter Information; and no such documents were filed with the Commission since the Commission&#8217;s
close of business on the business day immediately prior to the date of this Agreement and prior to the execution of this Agreement, except as set forth on Schedule II(c) hereto; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Registration Statement conforms, and the Prospectus and any further amendments or supplements to the Registration Statement and the
Prospectus will conform, in all material respects to the requirements of the Act and the rules and regulations of the Commission thereunder and do not and will not, as of the applicable effective date as to each part of the Registration Statement,
as of the applicable filing date as to the Prospectus and any amendment or supplement thereto, and as of each<B> </B>Time of Delivery, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or
necessary to make the statements therein not misleading; provided, however, that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with the Underwriter Information; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Other than as set forth or contemplated in the Registration Statement, the Pricing
Prospectus and the Prospectus, neither the Company nor any of its subsidiaries has, since the date of the latest audited financial statements included or incorporated by reference in the Registration Statement, the Pricing Prospectus and the
Prospectus, (i)&nbsp;sustained any material loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree or
(ii)&nbsp;entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is
material to the Company and its subsidiaries taken as a whole; and, since the respective dates as of which information is given in the Registration Statement, the Pricing Prospectus and the Prospectus, there has not been (x)&nbsp;any change in the
capital stock of the Company (other than as a result of (i)&nbsp;the exercise, if any, of stock options or the award, if any, of stock options, restricted stock, restricted stock units or other awards in the ordinary course of business pursuant to
the Company&#8217;s equity plans that are described in the Pricing Prospectus and the Prospectus or (ii)&nbsp;the issuance, if any, of shares of Common Stock upon conversion of Company securities as described in the Pricing Prospectus and the
Prospectus) or (y)&nbsp;any Material Adverse Effect (as defined below); as used in this Agreement, &#8220;Material Adverse Effect&#8221; shall mean any material adverse change or effect, or any development involving a prospective material adverse
change or effect, in or affecting (i)&nbsp;the business, properties, general affairs, management, financial position, stockholders&#8217; equity, results of operations or prospects of the Company and its subsidiaries, taken as a whole, except as set
forth or contemplated in the Pricing Prospectus, or (ii)&nbsp;the ability of the Company to issue and sell the Shares; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Neither the
Company nor any of its subsidiaries owns any real property and the Company and its subsidiaries have good and marketable title to all personal property owned by them (other than with respect to Intellectual Property (as defined below), which is
addressed exclusively in subsection (gg) below), in each case free and clear of all liens, encumbrances and defects except such as are described in the Pricing Prospectus or such as do not materially affect the value of such property and do not
interfere with the use made and proposed to be made of such property by the Company and its subsidiaries; and any real property and buildings held under lease by the Company and its subsidiaries are, to the Company&#8217;s knowledge, held by them
under valid, subsisting and enforceable leases with such exceptions as are not material and do not materially interfere with the use made and proposed to be made of such property and buildings by the Company and its subsidiaries; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) The Company has been (i)&nbsp;duly organized and is validly existing and in good standing under the laws of its jurisdiction of
organization, with power and authority (corporate and other) to own and/or lease its properties and conduct its business as described in the Registration Statement, the Pricing Prospectus and the Prospectus, and (ii)&nbsp;duly qualified as a foreign
corporation for the transaction of business and is in good standing (where such concept exists) under the laws of each other jurisdiction in which it owns or leases properties or conducts any business so as to require such qualification, except, in
the case of this clause (ii), where the failure to be so qualified or in good standing (where such concept exists) would not, individually or in the aggregate, have a Material Adverse Effect. Each of the Company&#8217;s subsidiaries (i)&nbsp;has
been, to the Company&#8217;s knowledge, duly organized, and is validly existing and in good standing (where such concept exists) under the laws of its jurisdiction of organization, with power and authority (corporate and other) to own and/or lease
its properties and conduct its business as described in the Registration Statement, the Pricing Prospectus and the Prospectus, and (ii)&nbsp;has been duly qualified as a foreign corporation for the transaction of business and is in good standing
(where such concept exists) under the laws of each other jurisdiction in which it owns or leases properties or conducts any business so as to require such qualification, except, in the case of this clause (ii), where the failure to be so qualified
or in good standing (where such concept exists) would not, individually or in the aggregate, have a Material Adverse Effect, and each subsidiary of the Company has been included in exhibit 21.1 to the Company&#8217;s Annual Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;for</FONT> its most recently completed fiscal year, other than as permitted by Item 601(b)(21) of Regulation <FONT STYLE="white-space:nowrap">S-K;</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Company has an authorized capitalization as set forth in the Pricing Prospectus and
all of the issued shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and conform in all material respects to the description of the
Common Stock contained in the Registration Statement, the Pricing Prospectus and the Prospectus; to the Company&#8217;s knowledge, all of the issued shares of capital stock of each subsidiary of the Company have been duly and validly authorized and
issued, and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> (except, in the case of any foreign subsidiary, for directors&#8217; qualifying shares); and all of the issued shares of capital stock of each subsidiary of the
Company are owned directly or indirectly by the Company, free and clear of all liens, encumbrances, equities or claims, except for such liens and encumbrances described in the Registration Statement, the Pricing Prospectus and the Prospectus; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) The Shares to be issued and sold by the Company to the Underwriters hereunder have been duly and validly authorized and, when issued and
delivered against payment therefor as provided herein, will be duly and validly issued and fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and will conform in all material respects to the description of the Common Stock
contained in the Pricing Disclosure Package and the Prospectus; and the issuance of the Shares is not subject to any preemptive or similar rights except as have been validly waived or complied with; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) The issue and sale of the Shares and the compliance by the Company with this Agreement and the consummation of the transactions
contemplated in this Agreement and the Pricing Prospectus will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, (i)&nbsp;any indenture, mortgage, deed of trust, loan agreement,
lease or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is
subject, (ii)&nbsp;the certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> (or other applicable organizational document) of the Company or any of its subsidiaries, or (iii)&nbsp;any statute or any judgment, order, rule or
regulation of any court or governmental agency or body having jurisdiction over the Company or any of its subsidiaries or any of their properties, except, in the case of clauses (i)&nbsp;or (iii), for such defaults, breaches, or violations that
would not, individually or in the aggregate, have a Material Adverse Effect; and no consent, approval, authorization, order, registration or qualification of or with any such court or governmental agency or body is required for the issue and sale of
the Shares or the consummation by the Company of the transactions contemplated by this Agreement, except such as have been obtained under the Act, the approval by the Financial Industry Regulatory Authority, Inc. (&#8220;FINRA&#8221;) of the
underwriting terms and arrangements and such consents, approvals, authorizations, registrations or qualifications as may be required under state securities or Blue Sky laws in connection with the purchase and distribution of the Shares by the
Underwriters; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) Neither the Company nor any of its subsidiaries is (i)&nbsp;in violation of its certificate of incorporation or <FONT
STYLE="white-space:nowrap">by-laws</FONT> (or other applicable organizational document), (ii) in violation of any statute or any judgment, order, rule or regulation of any court or governmental agency or body having jurisdiction over the Company or
any of its subsidiaries or any of their properties, or (iii)&nbsp;in default in the performance or observance of any obligation, agreement, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement, lease or other
agreement or instrument to which it is a party or by which it or any of its properties may be bound, except, in the case of the foregoing clauses (ii)&nbsp;and (iii), for such violations or defaults as would not, individually or in the aggregate,
have a Material Adverse Effect; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) The statements set forth in the Pricing Prospectus and Prospectus under the caption
&#8220;Description of Capital Stock&#8221;, insofar as they purport to constitute a summary of the terms of the Common Stock, and under the caption &#8220;Material United States Federal Income Tax Consequences for
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders of Our Common Stock&#8221;, insofar as they purport to describe the provisions of the laws and documents referred to therein, are accurate and fair in all material respects; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) [Reserved]; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) Other than
as set forth in the Registration Statement, the Pricing Prospectus and the Prospectus, there are no legal or governmental proceedings pending to which the Company or any of its subsidiaries or, to the Company&#8217;s knowledge, any officer or
director of the Company, is a party or of which any property of the Company or any of its subsidiaries is the subject which, if determined adversely to the Company or any of its subsidiaries (or such officer or director), would individually or in
the aggregate have a Material Adverse Effect; and, to the Company&#8217;s knowledge, no such proceedings are threatened or contemplated by governmental authorities or others; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) The Company is not and, after giving effect to the offering and sale of the Shares and the application of the proceeds thereof, will not be
an &#8220;investment company&#8221;, as such term is defined in the Investment Company Act of 1940, as amended; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) (A)&nbsp;(i) At the
time of filing the Registration Statement, (ii)&nbsp;at the time of the most recent amendment thereto for the purposes of complying with Section&nbsp;10(a)(3) of the Act (whether such amendment was by post-effective amendment, incorporated report
filed pursuant to Section&nbsp;13 or 15(d) of the Exchange Act or form of prospectus), and (iii)&nbsp;at the time the Company or any person acting on its behalf (within the meaning, for this clause only, of Rule 163(c) under the Act) made any offer
relating to the Shares in reliance on the exemption of Rule 163 under the Act, the Company was a &#8220;well-known seasoned issuer&#8221; as defined in Rule 405 under the Act; and (B)&nbsp;at the time of filing the Registration Statement and any
post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the Act) of the Shares, and at the date hereof, the Company was not and
is not an &#8220;ineligible issuer,&#8221; as defined under Rule 405 under the Act; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) Ernst&nbsp;&amp; Young LLP, who have certified
certain financial statements of the Company and its subsidiaries, are independent public accountants as required by the Act and the rules and regulations of the Commission thereunder; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) The Company maintains a system of internal control over financial reporting (as such term is defined in Rule
<FONT STYLE="white-space:nowrap">13a-15(f)</FONT> under the Exchange Act) that (i)&nbsp;has been designed by the Company&#8217;s principal executive officer and principal financial officer, or under their supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and (ii)&nbsp;is designed to provide reasonable assurance that
(A)&nbsp;transactions are executed in accordance with management&#8217;s general or specific authorization, (B)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted
accounting principles and to maintain accountability for assets, (C)&nbsp;access to assets is permitted only in accordance with management&#8217;s general or specific authorization, (D)&nbsp;the recorded
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences and (E)&nbsp;interactive data in eXtensible
Business Reporting Language included or incorporated by reference in the Registration Statement, the Pricing Prospectus and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the
Commission&#8217;s rules and guidelines applicable thereto. The Company is not aware of any material weaknesses in its internal control over financial reporting; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(t) The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the
Pricing Disclosure Package and the Prospectus fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto to the extent required; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(u) Since the date of the latest audited financial statements included or incorporated by reference in the Pricing Prospectus, there has been
no change in the Company&#8217;s internal control over financial reporting that has materially and adversely affected, or is reasonably likely to materially and adversely affect, the Company&#8217;s internal control over financial reporting; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) The Company maintains disclosure controls and procedures (as such term is defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT>
under the Exchange Act) that have been designed to ensure that material information relating to the Company and its subsidiaries is made known to the Company&#8217;s principal executive officer and principal financial officer by others within the
Company; and such disclosure controls and procedures are effective in all material respects; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(w) This Agreement has been duly authorized,
executed and delivered by the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any
director, officer, agent, employee, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries has (i)&nbsp;made, offered, promised or authorized any unlawful contribution, gift, entertainment or other
unlawful expense; (ii)&nbsp;made, offered, promised or authorized any direct or indirect unlawful payment; or (iii)&nbsp;violated or is in violation of any applicable provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, the UK
Bribery Act 2010 or any other applicable anti-bribery or anti-corruption law; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(y) The operations of the Company and its subsidiaries are
and have been conducted at all times in compliance with the requirements of applicable anti-money laundering laws, including, but not limited to, the Bank Secrecy Act of 1970, as amended by the USA PATRIOT ACT of 2001, and the rules and regulations
promulgated thereunder, and the anti-money laundering laws of the various jurisdictions in which the Company and its subsidiaries conduct business (collectively, the &#8220;Money Laundering Laws&#8221;) and no action, suit or proceeding by or before
any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(z) Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee or affiliate
of the Company or any of its subsidiaries is currently the subject or the target of any sanctions administered or enforced by the U.S. Government, including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the
Treasury (&#8220;OFAC&#8221;), or the U.S. Department of State and including, without </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limitation, the designation as a &#8220;specially designated national&#8221; or &#8220;blocked person,&#8221; the European Union, His Majesty&#8217;s Treasury, the United Nations Security
Council, or other relevant sanctions authority (collectively, &#8220;Sanctions&#8221;), nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or target of Sanctions, and the
Company will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or
facilitate any activities of or business with any person, or in any country or territory (including the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#8217;s Republic, the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk
People&#8217;s Republic, Cuba, Iran, North Korea, Syria and the Crimea Region of the Ukraine) that, at the time of such funding, is the subject or the target of Sanctions, or (ii)&nbsp;in any other manner that will result in a violation by any
person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(aa)
The financial statements included or incorporated by reference in the Registration Statement, the Pricing Prospectus and the Prospectus, together with the related schedules and notes, present fairly in all material respects the financial position of
the Company and its subsidiaries at the dates indicated and the statement of operations, stockholders&#8217; equity and cash flows of the Company and its subsidiaries for the periods specified; said financial statements have been prepared in
conformity with U.S. generally accepted accounting principles applied on a consistent basis throughout the periods involved. Any selected financial data and the summary financial information included in the Registration Statement, the Pricing
Prospectus and the Prospectus present fairly in all material respects the information shown therein and have been compiled on a basis consistent with that of the audited financial statements included or incorporated by reference therein. Except as
included or incorporated by reference therein, no historical or pro forma financial statements or supporting schedules are required to be included in the Registration Statement, the Pricing Prospectus or the Prospectus under the Act or the rules and
regulations promulgated thereunder; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(bb) There are (and prior to the Time of Delivery, will be) no debt securities or preferred stock
issued or guaranteed by the Company or any of its subsidiaries that are rated by a &#8220;nationally recognized statistical rating organization&#8221;, as such term is defined under Section&nbsp;3(a)(62) under the Exchange Act; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(cc) Except as described in the Registration Statement, the Pricing Prospectus and the Prospectus, the Company: (i)&nbsp;has operated and
currently operates its business in compliance in all material respects with applicable provisions of the Health Care Laws of the Food and Drug Administration (&#8220;FDA&#8221;), the Department of Health and Human Services (&#8220;HHS&#8221;) and
any comparable foreign or other regulatory authority to which they are subject (collectively, the &#8220;Applicable Regulatory Authorities&#8221;) applicable to the ownership, testing, development, manufacture, packaging, processing, use,
distribution, storage, import, export or disposal of any of the Company&#8217;s product candidates or any product manufactured or distributed by the Company; (ii)&nbsp;has not received any FDA Form 483, written notice of adverse finding, warning
letter, untitled letter or other correspondence or written notice from any court or arbitrator or the Applicable Regulatory Authorities alleging or asserting <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any Health Care Laws or any
licenses, certificates, approvals, clearances, exemptions, authorizations, permits and supplements or amendments thereto required by any such Health Care Laws (&#8220;Regulatory Authorizations&#8221;); (iii) possesses all Regulatory Authorizations
required to conduct its business as currently conducted and such Regulatory Authorizations are valid and in full force and effect and the Company is not in violation, in any material respect, of any term of any such Regulatory Authorizations;
(iv)&nbsp;has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or the Applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Regulatory Authorities or any other third party alleging that any product operation or activity is in material violation of any Health Care Laws and has no knowledge that the Applicable
Regulatory Authorities or any other third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (v)&nbsp;has not received notice that any of the Applicable Regulatory Authorities has taken, is
taking or intends to take action to limit, suspend, modify or revoke any material Regulatory Authorizations and has no knowledge that any of the Applicable Regulatory Authorities is considering such action; (vi)&nbsp;has filed, obtained, maintained
or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws or Regulatory Authorizations and that all such reports, documents, forms,
notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were materially corrected or supplemented by a subsequent submission); (vii) is not a party to and does not
have any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any
Applicable Regulatory Authority; and (viii)&nbsp;along with its employees, officers and directors, has not been excluded, suspended or debarred from participation in any government health care program or human clinical research, and, to the
knowledge of the Company, is not subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The term &#8220;Health Care Laws&#8221; means Title XVIII of the Social Security Act, 42 U.S.C. &#167;&#167; 1395 et seq. (the Medicare
statute); Title XIX of the Social Security Act, 42 U.S.C. &#167;&#167; 1396 et seq. (the Medicaid statute); the Federal Anti-Kickback Statute, 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(b);</FONT> the civil False Claims Act, 31
U.S.C. &#167;&#167; 3729 et seq.; the criminal False Claims Act 42 U.S.C. <FONT STYLE="white-space:nowrap">1320a-7b(a);</FONT> any criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287 and
the criminal health care fraud statutes set forth at 18 U.S.C. Sec. 1347 and 1349 under the Health Insurance Portability and Accountability Act of 1996, 42 U.S.C. &#167;&#167; 1320d et seq., (&#8220;HIPAA&#8221;); the Civil Monetary Penalties Law,
42 U.S.C. &#167;&#167; <FONT STYLE="white-space:nowrap">1320a-7a;</FONT> the Physician Payments Sunshine Act, 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7h;</FONT> the Exclusion Laws, 42 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">1320a-7;</FONT> HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, 42 U.S.C. &#167;&#167; 17921 et seq.; the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. &#167;&#167; 301
et seq.; the Public Health Service Act, 42 U.S.C. &#167;&#167; 201 et seq.; the regulations promulgated pursuant to such laws; and any similar federal, state and local laws and regulations; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(dd) Except as described in the Registration Statement, the Pricing Prospectus and the Prospectus, none of the Company&#8217;s product
candidates have received marketing approval from any Applicable Regulatory Authority. All clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and trials conducted by or on behalf of or sponsored by the Company, or in which the
Company has participated, with respect to the Company&#8217;s product candidates, including any such studies and trials that are described in the Registration Statement and the Prospectus, or the results of which are referred to in the Registration
Statement and the Prospectus, as applicable (collectively, &#8220;Company Trials&#8221;), were, and if still pending are, to the Company&#8217;s knowledge, being conducted in all material respects in accordance with all applicable Health Care Laws
of the Applicable Regulatory Authorities and current Good Clinical Practices and Good Laboratory Practices, standard medical and scientific research procedures and any applicable rules, regulations and policies of the jurisdiction in which such
trials and studies are being conducted; the descriptions in the Registration Statement, Pricing Prospectus and the Prospectus of the results of any Company Trials are accurate and complete descriptions in all material respects and fairly present the
data derived therefrom; the Company has no knowledge of any other studies or trials not described in the Registration Statement, the Pricing Prospectus and the Prospectus, the results of which are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inconsistent with or call into question the results described or referred to in the Registration Statement, the Pricing Prospectus and the Prospectus; the Company has not received any written
notices, correspondence or other communications from the Applicable Regulatory Authorities or any other governmental entity requiring or threatening the termination, material modification or suspension of Company Trials, other than ordinary course
communications with respect to modifications in connection with the design and implementation of such studies or trials, and, to the Company&#8217;s knowledge, there are no reasonable grounds for the same. No investigational new drug application or
comparable submission filed by or on behalf of the Company with the FDA has been terminated or suspended by the FDA or any other Applicable Regulatory Authority. The Company has obtained (or caused to be obtained) informed consent by or on behalf of
each human subject who participated in a Company Trial. To the Company&#8217;s knowledge, none of the Company Trials involved any investigator who has been disqualified as a clinical investigator or has been found by the FDA to have engaged in
scientific misconduct; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ee) The Company is, and at all prior times was, in compliance with all applicable data privacy and security laws
and regulations, including without limitation, as applicable, HIPAA, as amended, and the Company has taken any required and necessary actions to comply in all material respects with the European Union General Data Protection Regulation
(&#8220;GDPR&#8221;) (EU 2016/679) (and all other applicable laws and regulations with respect to Personal Data that have been announced as of the date hereof as becoming effective within 12 months after the date hereof, and for which any <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with the same would be reasonably likely to create a material liability) as soon as they take effect (collectively, the &#8220;Privacy Laws&#8221;), in each case, except as would not have a Material
Adverse Effect. The Company is not a &#8220;covered person&#8221; as that term is defined in Executive Order 14117 and rules and regulations issued thereunder, including&nbsp;28 C.F.R. Part 202, as implemented or amended from time to time (the
&#8220;DSP&#8221;). The Company and its subsidiaries have not engaged in or directed any &#8220;covered data transaction&#8221; as that term is defined in the DSP, except in compliance with the DSP. To ensure material compliance with the Privacy
Laws, the Company has in place and is in material compliance with commercially reasonable policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the
&#8220;Policies&#8221;) as applicable. &#8220;Personal Data&#8221; means (i)&nbsp;a natural person&#8217;s name, street address, telephone number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or tax
identification number, driver&#8217;s license number, passport number, credit card number, bank information, or customer or account number; (ii)&nbsp;any information which would qualify as &#8220;personally identifying information&#8221; under the
Federal Trade Commission Act, as amended; (iii)&nbsp;Protected Health Information as defined by HIPAA; (iv) &#8220;personal data&#8221; as defined by GDPR; and (v)&nbsp;any other piece of information that allows the identification of such natural
person or permits the collection or analysis of any data related to an identified person&#8217;s health or sexual orientation. The Company has since inception made all disclosures to users or customers required by applicable laws and regulatory
rules or requirements, and has provided accurate notice of its Policies then in effect to its customers, employees, third party vendors and representatives as required by applicable laws and regulatory rules or requirements, except where the failure
to do so would not, individually or in the aggregate, have a Material Adverse Effect. None of such disclosures made or contained in any of the Policies have been inaccurate, misleading, deceptive or in violation of any Privacy Laws or Policies in
any material respect. The execution, delivery and performance of this Agreement or any other agreement referred to in this Agreement will not result in a breach or violation of any Privacy Laws or Policies. The Company further certifies that it:
(i)&nbsp;has not received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in
any such notice; (ii)&nbsp;is not currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree, or agreement that
imposes any obligation or liability under any Privacy Law; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ff) Except as would not reasonably be expected to have a Material Adverse Effect, the
Company and its subsidiaries&#8217; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#8220;IT Systems&#8221;) are (i)&nbsp;adequate for, and operate
and perform as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, and (ii)&nbsp;to the Company&#8217;s knowledge, free and clear of all bugs, errors, defects, Trojan horses, time
bombs, malware and other corruptants. The Company and its subsidiaries have implemented and maintained commercially reasonable controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the
integrity, continuous operation, redundancy and security of all IT Systems and data (including all personal, personally identifiable, sensitive, confidential or regulated data (collectively, &#8220;Data&#8221;)) used in connection with their
businesses, and, except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there have been no breaches, violations, outages or known unauthorized uses of or known accesses to the same, except for those
that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same and except as would not reasonably be expected to have a Material
Adverse Effect. The Company and its subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies
and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except where the failure to be in compliance
would not reasonably be expected to have a Material Adverse Effect; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(gg) Except as disclosed in the Registration Statement, the Pricing
Prospectus and the Prospectus, the Company and its subsidiaries own or have obtained valid and enforceable licenses for, the inventions, patent applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other
intellectual property described in the Registration Statement, the Pricing Prospectus and the Prospectus as being owned or licensed by them or which are necessary for the conduct of their respective businesses as currently conducted or as currently
proposed to be conducted in the Registration Statement, the Pricing Prospectus and the Prospectus (collectively, &#8220;Intellectual Property&#8221;). Except as disclosed in the Registration Statement, the Pricing Prospectus and the Prospectus, to
the Company&#8217;s knowledge: (i)&nbsp;there are no third parties who have rights to any Intellectual Property, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the
Registration Statement and the Prospectus as licensed to the Company or any of its subsidiaries; (ii)&nbsp;there is no infringement or misappropriation by third parties of any Intellectual Property; (iii)&nbsp;neither the Company nor any of its
subsidiaries is infringing or misappropriating the intellectual property rights of third parties; and (iv)&nbsp;the Company and each of its subsidiaries is either the sole owner or the <FONT STYLE="white-space:nowrap">co-owner</FONT> of the
Intellectual Property owned by it and has the valid right to use such Intellectual Property. There is no pending or, to the Company&#8217;s knowledge, threatened action, suit, proceeding or claim by others: (A)&nbsp;challenging the Company&#8217;s
or any of its subsidiaries&#8217; rights in or to any Intellectual Property; (B)&nbsp;challenging the validity, enforceability or scope of any Intellectual Property; or (C)&nbsp;asserting that either the Company or any of its subsidiaries infringes
or otherwise violates, or would, upon the commercialization of any product or service described in the Registration Statement, the Pricing Prospectus and the Prospectus as under development, infringe, misappropriate or violate, any patent,
trademark, trade name, service name, copyright, trade secret or other proprietary rights of others. The Company and each of its subsidiaries have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or such subsidiary, and all such agreements are in full force and effect. Except
as disclosed in the Registration Statement, the Pricing Prospectus and the Prospectus, and in each case of clause (1), (2) and (3)&nbsp;below except as would not have a Material Adverse Effect, to the Company&#8217;s knowledge: (1)&nbsp;the Company
and its subsidiaries have complied in all material respects with the terms of each material agreement pursuant to which any permission to use Intellectual Property has been granted to the Company or its subsidiaries, the Company has not received any
written notice alleging any material breach of such agreements and is unaware of any facts which would form a reasonable basis for any such claim, and all such agreements are in full force and effect by the Company and its subsidiaries and, to the
knowledge of the Company, by all counterparties to such agreements; (2)&nbsp;all employees or contractors engaged in the development of Intellectual Property on behalf of the Company or its subsidiaries have executed a written agreement containing
an enforceable invention assignment to the Company of such person&#8217;s rights, title and interest in and to such Intellectual Property, and to the knowledge of the Company, no such agreement has been breached or violated; and (3)&nbsp;no
government funding, facilities or resources of a university, college, other educational institution or research center was used in the development of any Intellectual Property that are owned or purported to be owned by the Company that would confer
any governmental agency or body, university, college, other educational institution or research center any claim or right of ownership to any such Company Intellectual Property; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(hh) Except as described in the Registration Statement, the Pricing Prospectus and the Prospectus, all patents and patent applications owned by
or licensed to the Company or its subsidiaries under which the Company or any of its subsidiaries has rights have, to the knowledge of the Company, been duly and properly filed and maintained; to the knowledge of the Company, the parties prosecuting
such applications have complied with their duty of candor and disclosure to the U.S. Patent and Trademark Office (the &#8220;USPTO&#8221;) in connection with such applications; and the Company is not aware of any facts required to be disclosed to
the USPTO that were not disclosed to the USPTO and which would preclude the grant of a patent in connection with any such application or would reasonably be expected to form the basis of a finding of invalidity with respect to any patents that have
been issued with respect to such applications; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) There are no persons with registration rights or other similar rights to have any
securities registered pursuant to the Registration Statement or otherwise registered by the Company under the Act except as have been validly waived or complied with; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(jj) No labor disturbance by or dispute with the employees of the Company or any of its subsidiaries exists or, to the knowledge of the Company
or any of its subsidiaries, is contemplated or threatened, and the Company and its subsidiaries are not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of its principal suppliers, manufacturers,
customers or contractors, which, in either case, would, individually or in the aggregate, result in a Material Adverse Effect; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(kk) Except
as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect: (i)&nbsp;each employee benefit plan, within the meaning of Section&nbsp;3(3) of the Employee Retirement Income Security Act of 1974, as
amended (&#8220;ERISA&#8221;), for which the Company or any member of its &#8220;Controlled Group&#8221; (defined as any entity, whether or not incorporated, that is under common control with the Company within the meaning of
Section&nbsp;4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section&nbsp;414(b),(c),(m) or (o)&nbsp;of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;)) would have any
liability (each, a &#8220;Plan&#8221;) has been maintained in compliance with its terms </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code and no prohibited transaction, within the meaning of
Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative exemption; (ii)&nbsp;none of the Plans are subject to the funding rules of
Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA; (iii)&nbsp;none of the Plans are &#8220;multiemployer plans&#8221; within the meaning of Section&nbsp;4001(a)(3) of ERISA; and (iv)&nbsp;each Plan that is intended to be qualified under
Section&nbsp;401(a) of the Code is so qualified, and nothing has occurred, whether by action or failure to act, which would cause the loss of such qualification; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ll) The Company and its subsidiaries have paid all federal, state, local and foreign taxes and filed all tax returns required to be paid or
filed through the date hereof; and except as otherwise disclosed in each of the Registration Statement, the Pricing Prospectus and the Prospectus, there is no tax deficiency that has been asserted against the Company or any of its subsidiaries or
any of their respective properties or assets; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(mm) (i) The Company and its subsidiaries (x)&nbsp;are in compliance with all, and have not
violated any, applicable federal, state, local and foreign laws, rules, regulations, requirements, decisions, judgments, decrees, orders and other legally enforceable requirements relating to pollution or the protection of human health or safety,
the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &#8220;Environmental Laws&#8221;); (y) have received and are in compliance with all, and have not violated any, permits, licenses,
certificates or other authorizations or approvals required of them under any Environmental Laws to conduct their respective businesses; and (z)&nbsp;have not received written notice of any actual or potential liability or obligation under or
relating to, or any actual or potential violation of, any Environmental Laws, including for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, and have no knowledge of
any event or condition that would reasonably be expected to result in any such notice, and (ii)&nbsp;there are no costs or liabilities associated with Environmental Laws of or relating to the Company or its subsidiaries, except in the case of each
of (i)&nbsp;and (ii) above, for any such matter as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and (iii)&nbsp;except as described in each of the Registration Statement, the Pricing
Prospectus and the Prospectus, (x)&nbsp;there is no proceeding that is pending, or that is known by the Company to be contemplated, against the Company or any of its subsidiaries under any Environmental Laws in which a governmental entity is also a
party, other than such proceeding regarding which the Company reasonably believes no monetary sanctions of $100,000 or more will be imposed, (y)&nbsp;the Company and its subsidiaries are not aware of any facts or issues regarding compliance with
Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or contaminants, that would, individually or in the aggregate, reasonably be excepted to have a
Material Adverse Effect, and (z)&nbsp;none of the Company or its subsidiaries anticipates material capital expenditures relating to any Environmental Laws; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(nn) There are no business relationships or related-party transactions involving the Company or any subsidiary or any other person required to
be disclosed in the Pricing Prospectus or the Prospectus that have not been described as required; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(oo) The Company and its subsidiaries
have insurance covering their respective properties, operations, personnel and businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as are generally maintained by similarly
situated companies and which the Company believes are reasonably </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adequate to protect the Company and its subsidiaries and their respective businesses; and neither the Company nor any of its subsidiaries has (i)&nbsp;received notice from any insurer or agent of
such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance or (ii)&nbsp;any reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(pp) The Company qualifies as an &#8220;experienced issuer&#8221; (within the meaning of FINRA Rule 5110(j)(6)) for purposes of the exemption
from filing under FINRA Rule 5110(h)(1)(C). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(qq) Neither the Company nor any of its subsidiaries is a party to any contract, agreement or
understanding with any person (other than this Agreement) that would give rise to a valid claim against any of them or any Underwriter for a brokerage commission, finder&#8217;s fee or like payment in connection with the offering and sale of the
Shares; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(rr) Nothing has come to the attention of the Company that has caused the Company to believe that the statistical and
market-related data included or incorporated by reference in each of the Registration Statement, the Pricing Prospectus and the Prospectus is not based on or derived from sources that are reliable and accurate in all material respects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ss) Neither the Company nor any of its subsidiaries is a &#8220;covered foreign person&#8221;, as that term is defined 31 C.F.R. &#167;
850.209. The Company does not currently engage, directly or indirectly, in&nbsp;a &#8220;covered activity&#8221; as that term is defined in 31 C.F.R. &#167; 850.208 (a &#8220;Covered Activity&#8221;). The Company does not have any joint venture that
engages in or plans to engage in any Covered Activity. The Company also does not, directly or indirectly, hold a board seat on, have a voting or equity interest in, or have any contractual power to direct or cause the direction of the management or
policies of any person or persons that engages or plans to engage in any Covered Activity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. Subject to the terms and conditions herein
set forth, (a)&nbsp;the Company agrees to issue and sell to each of the Underwriters, and each of the Underwriters agrees, severally and not jointly, to purchase from the Company, at a purchase price per share of $8.0325, the number of Firm Shares
set forth opposite the name of such Underwriter in Schedule I hereto and (b)&nbsp;in the event and to the extent that the Underwriters shall exercise the election to purchase Optional Shares as provided below, the Company agrees to issue and sell to
each of the Underwriters, and each of the Underwriters agrees, severally and not jointly, to purchase from the Company, at the purchase price per share set forth in clause (a)&nbsp;of this Section&nbsp;2 (provided that the purchase price per
Optional Share shall be reduced by an amount per share equal to any dividends or distributions declared by the Company and payable on the Firm Shares but not payable on the Optional Shares), that portion of the number of Optional Shares as to which
such election shall have been exercised (to be adjusted by the Representatives so as to eliminate fractional shares) determined by multiplying such number of Optional Shares by a fraction, the numerator of which is the maximum number of Optional
Shares which such Underwriter is entitled to purchase as set forth opposite the name of such Underwriter in Schedule I hereto and the denominator of which is the maximum number of Optional Shares that all of the Underwriters are entitled to purchase
hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company hereby grants to the Underwriters the right to purchase at their election up to 2,647,058 Optional Shares, at the
purchase price per share set forth in the paragraph above, provided that the purchase price per Optional Share shall be reduced by an amount per share equal to any dividends or distributions declared by the Company and payable on the Firm Shares
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
but not payable on the Optional Shares. Any such election to purchase Optional Shares may be exercised only by written notice from the Representatives to the Company, given within a period of 30
calendar days after the date of this Agreement, setting forth the aggregate number of Optional Shares to be purchased and the date on which such Optional Shares are to be delivered, as determined by the Representatives but in no event earlier than
the First Time of Delivery (as defined in Section&nbsp;4 hereof) or, unless the Representatives and the Company otherwise agree in writing, earlier than one or later than ten business days after the date of such notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3. Upon the authorization by you of the release of the Firm Shares, the several Underwriters propose to offer the Firm Shares for sale upon the
terms and conditions set forth in the Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4. (a) The Shares to be purchased by each Underwriter
hereunder, in book-entry form, and in such authorized denominations and registered in such names as the Representatives may request upon at least twenty-four hours&#8217; prior notice to the Company shall be delivered by or on behalf of the Company
to the Representatives, through the facilities of the Depository Trust Company (&#8220;DTC&#8221;), for the account of such Underwriter, against payment by or on behalf of such Underwriter of the purchase price therefor by wire transfer of Federal <FONT
STYLE="white-space:nowrap">(same-day)</FONT> funds to the account specified by the Company to the Representatives at least twenty-four hours in advance. The time and date of such delivery and payment shall be, with respect to the Firm Shares,
9:30&nbsp;a.m., New York City time, on February&nbsp;27, 2026 or such other time and date as the Representatives and the Company may agree upon in writing, and, with respect to the Optional Shares, 9:30 a.m., New York time, on the date specified by
the Representatives in the written notice given by the Representatives of the Underwriters&#8217; election to purchase such Optional Shares, or such other time and date as the Representatives and the Company may agree upon in writing. Such time and
date for delivery of the Firm Shares is herein called the &#8220;First Time of Delivery&#8221;, such time and date for delivery of the Optional Shares, if not the First Time of Delivery, is herein called the &#8220;Second Time of Delivery&#8221;,
and each such time and date for delivery is herein called a &#8220;Time of Delivery&#8221;. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The documents to be delivered at each Time
of Delivery by or on behalf of the parties hereto pursuant to Section&nbsp;8 hereof, including the cross receipt for the Shares and any additional documents requested by the Underwriters pursuant to Section&nbsp;8(o) hereof, will be delivered at the
offices of Latham&nbsp;&amp; Watkins LLP, 650 Town Center Drive, Floor 20, Costa Mesa, CA 92626 (the &#8220;Closing Location&#8221;), and the Shares will be delivered at the office of DTC or its designated custodian (the &#8220;Designated
Office&#8221;), all at such Time of Delivery. A meeting will be held at the Closing Location at 9:00 p.m., New York City time, on the New York Business Day next preceding such Time of Delivery, at which meeting the final drafts of the documents to
be delivered pursuant to the preceding sentence will be available for review by the parties hereto. For the purposes of this Section&nbsp;4, &#8220;New York Business Day&#8221; shall mean each Monday, Tuesday, Wednesday, Thursday and Friday which is
not a day on which banking institutions in New York City are generally authorized or obligated by law or executive order to close. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5. The
Company agrees with each of the Underwriters: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) To prepare the Prospectus in a form approved by you and to file such Prospectus pursuant
to Rule 424(b) under the Act prior to the earlier of (i)&nbsp;the First Time of Delivery and (ii)&nbsp;the Commission&#8217;s close of business on the second business day following the execution and delivery of this Agreement; to make no further
amendment or any supplement to the Registration Statement, the Base Prospectus or the Prospectus prior to the last Time of Delivery which shall be disapproved by you promptly after reasonable notice thereof; to advise you, promptly after it
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
receives notice thereof, of the time when any amendment to the Registration Statement has been filed or becomes effective or any amendment or supplement to the Prospectus has been filed and to
furnish you with copies thereof; to file promptly all other material required to be filed by the Company with the Commission pursuant to Rule 433(d) under the Act; to file promptly all reports and any definitive proxy or information statements
required to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus (or in lieu thereof, the notice
referred to in Rule 173(a) under the Act) is required in connection with the offering or sale of the Securities; to advise you, promptly after it receives notice thereof, of the issuance by the Commission of any stop order or of any order preventing
or suspending the use of any Preliminary Prospectus or other prospectus in respect of the Shares, of any notice of objection of the Commission to the use of the Registration Statement or any post-effective amendment thereto pursuant to Rule
401(g)(2) under the Act, of the suspension of the qualification of the Shares for offering or sale in any jurisdiction, of the initiation or threatening of any proceeding for any such purpose, including pursuant to Section&nbsp;8A under the Act, or
of any request by the Commission for the amending or supplementing of the Registration Statement or the Prospectus or for additional information; and, in the event of the issuance of any stop order or of any order preventing or suspending the use of
any Preliminary Prospectus or other prospectus or suspending any such qualification, to promptly use its best efforts to obtain the withdrawal of such order; and in the event of any such issuance of a notice of objection, promptly to take such steps
including, without limitation, amending the Registration Statement or filing a new registration statement, at its own expense, as may be necessary to permit offers and sales of the Shares by the Underwriters (references herein to the Registration
Statement shall include any such amendment or new registration statement); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If required by Rule 430B(h) under the Act, to prepare a
form of prospectus in a form approved by you and to file such form of prospectus pursuant to Rule 424(b) under the Act not later than may be required by Rule 424(b) under the Act; and to make no further amendment or supplement to such form of
prospectus which shall be disapproved by you promptly after reasonable notice thereof; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If by the third anniversary (the &#8220;Renewal
Deadline&#8221;) of the initial effective date of the Registration Statement, any of the Shares remain unsold by the Underwriters, the Company will file, if it has not already done so and is eligible to do so, a new automatic shelf registration
statement relating to the Shares, in a form satisfactory to you. If at the Renewal Deadline the Company is no longer eligible to file an automatic shelf registration statement, the Company will, if it has not already done so, file a new shelf
registration statement relating to the Shares, in a form satisfactory to you and will use its best efforts to cause such registration statement to be declared effective within 180 days after the Renewal Deadline. The Company will take all other
action necessary or appropriate to permit the public offering and sale of the Shares to continue as contemplated in the expired registration statement relating to the Shares. References herein to the Registration Statement shall include such new
automatic shelf registration statement or such new shelf registration statement, as the case may be; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Promptly from time to time to
take such action as you may reasonably request to qualify the Shares for offering and sale under the securities laws of such jurisdictions as you may request and to comply with such laws so as to permit the continuance of sales and dealings therein
in such jurisdictions for as long as may be necessary to complete the distribution of the Shares, provided that in connection therewith the Company shall not be required to qualify as a foreign corporation (where not otherwise required) or to file a
general consent to service of process in any jurisdiction (where not otherwise required); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Prior to 10:00 a.m., New York City time, on the New York Business Day next succeeding
the date of this Agreement (or such other time as may be agreed to by the Representatives and the Company) and from time to time, to furnish the Underwriters with written and electronic copies of the Prospectus in New York City in such quantities as
you may reasonably request, and, if the delivery of a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) is required at any time prior to the expiration of nine months after the time of issue of the Prospectus in
connection with the offering or sale of the Shares and if at such time any event shall have occurred as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state any
material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made when such Prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act)<B> </B>is delivered, not
misleading, or, if for any other reason it shall be necessary during such same period to amend or supplement the Prospectus or to file under the Exchange Act any document incorporated by reference in the Prospectus in order to comply with the Act or
the Exchange Act, to notify you and upon your request to file such document and to prepare and furnish without charge to each Underwriter and to any dealer in securities as many written and electronic copies as you may from time to time reasonably
request of an amended Prospectus or a supplement to the Prospectus which will correct such statement or omission or effect such compliance; and in case any Underwriter is required to deliver a prospectus (or in lieu thereof, the notice referred to
in Rule 173(a) under the Act)<B> </B>in connection with sales of any of the Shares at any time nine months or more after the time of issue of the Prospectus, upon your request but at the expense of such Underwriter, to prepare and deliver to such
Underwriter as many written and electronic copies as you may request of an amended or supplemented Prospectus complying with Section&nbsp;10(a)(3) of the Act; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) To make generally available to its securityholders as soon as practicable (which may be satisfied by filing with the Commission&#8217;s
Electronic Data Gathering Analysis and Retrieval System (&#8220;EDGAR&#8221;)), but in any event not later than sixteen months after the effective date of the Registration Statement (as defined in Rule 158(c) under the Act), an earnings statement of
the Company and its subsidiaries (which need not be audited) complying with Section&nbsp;11(a) of the Act and the rules and regulations of the Commission thereunder (including, at the option of the Company, Rule 158); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) During the period beginning from the date hereof and continuing to and including the date 60 days after the date of the Prospectus (the <FONT
STYLE="white-space:nowrap">&#8220;Lock-Up</FONT> Period&#8221;), not to (i)&nbsp;offer, sell, contract to sell, pledge, lend, grant any option to purchase, make any short sale or otherwise transfer or dispose of, directly or indirectly, or file with
the Commission a registration statement under the Act relating to, any securities of the Company that are substantially similar to the Shares, including but not limited to any options or warrants to purchase shares of Common Stock or any securities
that are convertible into or exchangeable for, or that represent the right to receive, Common Stock or any such substantially similar securities, or publicly disclose the intention to make any offer, sale, pledge, loan, disposition, confidential
submission or filing or (ii)&nbsp;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or any such other securities, whether any such transaction described in
clauses (i)&nbsp;or (ii) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise, or (iii)&nbsp;publicly disclose the intention to do any of the foregoing, in each case, without the prior written consent of
Goldman Sachs&nbsp;&amp; Co. LLC and Leerink Partners LLC; provided, however, that the foregoing restrictions shall not apply to (1)&nbsp;the Shares to be sold hereunder, (2)&nbsp;any shares of Common Stock or any securities or other awards
(including without limitation options, restricted stock or restricted stock units) convertible into, exercisable for, or that represent the right to receive, shares of Common Stock pursuant to any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock option plan, incentive plan or stock purchase plan of the Company (collectively, &#8220;Company Stock Plans&#8221;) or otherwise in equity compensation arrangements described in the
Registration Statement and the Prospectus, provided that any directors or officers (as that term is defined in Section&nbsp;16 of the Exchange Act and Rule <FONT STYLE="white-space:nowrap">16a-1</FONT> thereunder) who are the recipients thereof have
provided to the Representatives a signed <FONT STYLE="white-space:nowrap">lock-up</FONT> letter substantially in the form of Annex I hereto, (3)&nbsp;any shares of Common Stock issued upon the conversion, exercise or exchange of convertible,
exercisable or exchangeable securities, including convertible notes, outstanding on the date of this Agreement, in each case if such convertible, exercisable or exchangeable securities is described in the Registration Statement and the Prospectus
and the holders of such convertible, exercisable or exchangeable securities have provided to the Representatives a signed lockup-letter substantially in the form of Annex I hereto, (4)&nbsp;the filing by the Company of any registration statement on
Form <FONT STYLE="white-space:nowrap">S-8</FONT> or a successor form thereto relating to any Company Stock Plan described in the Registration Statement and the Prospectus, (5) 7,239,382 shares of Common Stock the Company has agreed to issue pursuant
to the Stock Purchase Agreement dated February&nbsp;19, 2026 between the Company and Astellas US LLC, and (6)&nbsp;any shares of Common Stock or any securities convertible into or exchangeable for, or that represent the right to receive, shares of
Common Stock issued in connection with any joint venture, commercial or collaborative relationship or the acquisition or license by the Company of the securities, businesses, property or other assets of another person or entity or pursuant to any
employee benefit plan assumed by the Company in connection with any such acquisition, provided that in the case of clause (6), the aggregate number of shares that the Company may sell or issue or agree to sell or issue pursuant to clause (6), (x)
shall not exceed 10.0% of the total number of shares of Common Stock issued and outstanding immediately following the completion of the transactions contemplated by this Agreement and (y)&nbsp;the recipients thereof provide to the Representatives a
signed <FONT STYLE="white-space:nowrap">lock-up</FONT> letter substantially in the form of Annex I hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) To pay the required
Commission filing fees relating to the Shares within the time required by Rule 456(b)(1) under the Act without regard to the proviso therein and otherwise in accordance with Rules 456(b) and 457(r) under the Act; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) To use the net proceeds received by it from the sale of the Shares pursuant to this Agreement in the manner specified in the Pricing
Prospectus under the caption &#8220;Use of Proceeds&#8221;; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) To use its best efforts to<B> </B>list, subject to notice of issuance, the
Shares on the Nasdaq Stock Market (the &#8220;Nasdaq&#8221;); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) Upon request of any Underwriter, to furnish, or cause to be furnished,
to such Underwriter an electronic version of the Company&#8217;s trademarks, servicemarks and corporate logo for use on the website, if any, operated by such Underwriter for the purpose of facilitating the
<FONT STYLE="white-space:nowrap">on-line</FONT> offering of the Shares (the &#8220;License&#8221;); provided, however, that the License shall be used solely for the purpose described above, is granted without any fee and may not be assigned or
transferred; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) The Company will not take, directly or indirectly, without giving effect to activities by the Underwriters, any action
designed to or that would reasonably be expected to cause or result in any stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6. (a) The Company represents and agrees that, without the prior consent of the
Representatives, it has not made and will not make any offer relating to the Shares that would constitute a &#8220;free writing prospectus&#8221; as defined in Rule 405 under the Act; each Underwriter represents and agrees that, without the prior
consent of the Company and the Representatives, it has not made and will not make any offer relating to the Shares that would constitute a free writing prospectus required to be filed with the Commission; any such free writing prospectus the use of
which has been consented to by the Company and the Representatives is listed on Schedule&nbsp;II(a) or Schedule II(c) hereto; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The
Company has complied and will comply with the requirements of Rule 433 under the Act applicable to any Issuer Free Writing Prospectus, including timely filing with the Commission or retention where required and legending; and the Company represents
that it has satisfied and agrees that it will satisfy the conditions under Rule 433 under the Act to avoid a requirement to file with the Commission any electronic road show; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company agrees that if at any time following issuance of an Issuer Free Writing Prospectus or any Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication prepared or authorized by it any event occurred or occurs as a result of which such Issuer Free Writing Prospectus or Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication prepared or authorized by it would conflict with the information in the Registration Statement, the Pricing Prospectus or the Prospectus or
would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances then prevailing, not misleading, the Company will give prompt notice thereof
to the Representatives and, if requested by the Representatives, will prepare and furnish without charge to each Underwriter an Issuer Free Writing Prospectus, Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or other document which will correct such conflict, statement or omission, provided, however, that this representation and warranty
shall not apply to any statements or omissions in an Issuer Free Writing Prospectus or Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication prepared or authorized by it made in
reliance upon and in conformity with the Underwriter Information<B>;</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company represents and agrees that (i)&nbsp;it has not
engaged in, or authorized any other person to engage in, any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications, other than <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications with the prior consent of the Representatives with entities that are qualified institutional buyers as defined in Rule 144A under the Act or institutions that are accredited
investors as defined in Rule 501(a) under the Act; and (ii)&nbsp;it has not distributed, or authorized any other person to distribute, any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communications, other than those distributed with the prior consent of the Representatives that are listed on Schedule II(d) hereto; and the Company reconfirms that the Underwriters have been authorized to act on its behalf in engaging in <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Each Underwriter
represents and agrees that any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications undertaken by it were with entities that are qualified institutional buyers as defined in Rule 144A
under the Act or institutions that are accredited investors as defined in Rule 501(a) under the Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7. The Company covenants and agrees
with the several Underwriters that the Company will pay or cause to be paid the following: (i)&nbsp;the fees, disbursements and expenses of the Company&#8217;s counsel and accountants in connection with the registration of the Shares under the Act
and all other expenses in connection with the preparation, printing, reproduction and filing of the Registration Statement, the Base Prospectus, any Preliminary Prospectus, any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any Issuer Free Writing Prospectus and the Prospectus and amendments and supplements thereto and the mailing and delivering of copies
thereof to the Underwriters and dealers; (ii)&nbsp;the cost of printing or producing any Agreement among Underwriters, this Agreement, the Blue Sky Memorandum, closing documents (including any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
compilations thereof) and any other documents in connection with the offering, purchase, sale and delivery of the Shares; (iii)&nbsp;all expenses in connection with the qualification of the
Shares for offering and sale under state securities laws as provided in Section&nbsp;5(d) hereof, including the fees and disbursements of counsel for the Underwriters in connection with such qualification and in connection with the Blue Sky survey,
and including any stock or other transfer taxes payable upon the sale, issuance or delivery of the Shares to the Underwriters; (iv)&nbsp;all fees and expenses in connection with listing the Shares on the Nasdaq; (v)&nbsp;the cost of preparing stock
certificates; (vi)&nbsp;the cost and charges of any transfer agent or registrar; and (vii)&nbsp;all other costs and expenses incident to the performance of its obligations hereunder which are not otherwise specifically provided for in this Section;
provided, however, that the amounts payable by the Company pursuant to clause (iii)&nbsp;for fees and disbursements of counsel to the Underwriters described in clause (iii)&nbsp;shall not exceed $25,000 in the aggregate. It is understood, however,
that, except as provided in this Section, and Sections 9 and 11 hereof, the Underwriters will pay all of their own costs and expenses, including the fees of their counsel, stock transfer taxes on resale of any of the Shares by them, and any
advertising expenses connected with any offers they may make and all travel and lodging expenses of the Underwriters and their representatives and counsel. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8. The obligations of the Underwriters hereunder, as to the Shares to be delivered at each Time of Delivery, shall be subject, in their
discretion, to the condition that all representations and warranties and other statements of the Company herein are, at and as of the Applicable Time and such Time of Delivery, true and correct, the condition that the Company shall have performed
all of its obligations hereunder theretofore to be performed, and the following additional conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Prospectus shall have been
filed with the Commission pursuant to Rule 424(b) under the Act within the applicable time period prescribed for such filing by the rules and regulations under the Act and in accordance with Section&nbsp;5(a) hereof; all material required to be
filed by the Company pursuant to Rule 433(d) under the Act shall have been filed with the Commission within the applicable time period prescribed for such filing by Rule 433; no stop order suspending the effectiveness of the Registration Statement
or any part thereof shall have been issued and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Act shall have been initiated or threatened by the Commission and no notice of objection of the Commission to the use of the
Registration Statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Act shall have been received; no stop order suspending or preventing the use of the Pricing Prospectus, Prospectus or any Issuer Free Writing
Prospectus shall have been initiated or threatened by the Commission; and all requests for additional information on the part of the Commission shall have been complied with to your reasonable satisfaction; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Latham&nbsp;&amp; Watkins LLP, counsel for the Underwriters, shall have furnished to you such written opinion and negative assurance
letter, each dated for such Time of Delivery, in form and substance satisfactory to the Representatives, and such counsel shall have received such papers and information as they may reasonably request to enable them to pass upon such matters; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Gunderson Dettmer Stough Villeneuve Franklin&nbsp;&amp; Hachigian LLP, corporate counsel for the Company, shall have furnished to you their
written opinion and negative assurance letter, each dated for such Time of Delivery, in form and substance satisfactory to the Representatives; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Fox Rothschild LLP, intellectual property counsel for the Company, shall have furnished to you their written opinion, dated for such Time
of Delivery, in form and substance satisfactory to the Representatives; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Sheppard, Mullin, Richter&nbsp;&amp; Hampton LLP, intellectual property counsel for the
Company, shall have furnished to you their written opinion, dated for such Time of Delivery, in form and substance satisfactory to the Representatives; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Ropes&nbsp;&amp; Gray LLP, regulatory counsel for the Company, shall have furnished to you their written opinion, dated for such Time of
Delivery, in form and substance satisfactory to the Representatives; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) On the date of the Prospectus at a time after the execution of
this Agreement, at 9:30 a.m., New York City time, on the effective date of any <FONT STYLE="white-space:nowrap">post-effective</FONT> amendment to the Registration Statement filed subsequent to the date of this Agreement and also at each Time of
Delivery, Ernst&nbsp;&amp; Young LLP shall have furnished to you a letter or letters, dated the respective dates of delivery thereof, in form and substance satisfactory to the Representatives; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) [Reserved]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) (i)
Neither the Company nor any of its subsidiaries shall have sustained since the date of the latest audited financial statements included or incorporated by reference in the Pricing Prospectus any loss or interference with its business from fire,
explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree, otherwise than as set forth or contemplated in the Pricing Prospectus, and (ii)&nbsp;since the
respective dates as of which information is given in the Pricing Prospectus there shall not have been any change in the capital stock (other than as a result of the exercise of stock options or the award of stock options, restricted stock or
restricted stock units in the ordinary course of business pursuant to the Company&#8217;s equity plans that are described in the Pricing Prospectus) or long-term debt of the Company or any of its subsidiaries or any dividend or distribution of any
kind declared, set aside for payment, paid or made by the Company on any class of capital stock or any change or effect, or any development involving a prospective change or effect, in or affecting (x)&nbsp;the business, properties, general affairs,
management, financial position, stockholders&#8217; equity or results of operations of the Company and its subsidiaries, taken as a whole, except as set forth or contemplated in the Pricing Prospectus and the Prospectus, or (y)&nbsp;the ability of
the Company to perform its obligations under this Agreement, including the issuance and sale of the Shares, or to consummate the transactions contemplated in the Pricing Prospectus and the Prospectus, the effect of which, in any such case described
in clause (i)&nbsp;or (ii), is in your judgment so material and adverse as to make it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares being delivered at such Time of Delivery on the terms and in the
manner contemplated in the Pricing Prospectus and the Prospectus; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) On or after the Applicable Time there shall not have occurred any
of the following: (i)&nbsp;a suspension or material limitation in trading in securities generally on the New York Stock Exchange or on the Nasdaq; (ii)&nbsp;a suspension or material limitation in trading in the Company&#8217;s securities on the
Nasdaq; (iii)&nbsp;a general moratorium on commercial banking activities declared by either Federal or New York State authorities or a material disruption in commercial banking or securities settlement or clearance services in the United States;
(iv)&nbsp;the outbreak or escalation of hostilities involving the United States or the declaration by the United States of a national emergency or war or (v)&nbsp;the occurrence of any other calamity or crisis or any change in financial, political
or economic conditions in the United States or elsewhere, if the effect of any such event specified in clause (iv)&nbsp;or (v) in your judgment makes it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares
being delivered at such Time of Delivery on the terms and in the manner contemplated in the Pricing Prospectus and the Prospectus; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) The Shares to be sold at such Time of Delivery shall have been duly listed for quotation
on the Nasdaq; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms and arrangements;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) The Company shall have obtained and delivered to the Underwriters executed copies of an agreement from all officers (as that term is
defined in Section&nbsp;16 of the Exchange Act and Rule <FONT STYLE="white-space:nowrap">16a-1</FONT> thereunder) and directors of the Company, substantially to the effect set forth in Annex I hereof in form and substance satisfactory to you; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) The Company shall have complied with the provisions of Section&nbsp;5(e) hereof with respect to the furnishing of prospectuses on the New
York Business Day next succeeding the date of this Agreement (or such other time as may be agreed to by the Representatives and the Company); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) The Company shall have furnished or caused to be furnished to you at such Time of Delivery certificates of such officers of the Company
satisfactory to you as to the accuracy of the representations and warranties of the Company herein at and as of such Time of Delivery, as to the performance by the Company of all of its obligations hereunder to be performed at or prior to such Time
of Delivery, as to the matters set forth in subsections (a)&nbsp;and (i) of this Section and as to such other matters as you may reasonably request; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) At each Time of Delivery, the Representatives shall have received a certificate of the Secretary of the Company, as to such matters as the
Representatives may reasonably request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9. (a) The Company will indemnify and hold harmless each Underwriter against any losses, claims,
damages or liabilities, joint or several, to which such Underwriter may become subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue
statement or alleged untrue statement of a material fact contained in the Registration Statement, the Base Prospectus, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, any Issuer Free
Writing Prospectus, any &#8220;roadshow&#8221; as defined in Rule 433(h) under the Act (a &#8220;roadshow&#8221;), any &#8220;issuer information&#8221; filed or required to be filed pursuant to Rule 433(d) under the Act or any Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication prepared or authorized by the Company, or arise out of or are based upon the omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein not misleading, and will reimburse each Underwriter for any legal or other expenses reasonably incurred by such Underwriter in connection with investigating or defending any
such action or claim as such expenses are incurred; provided, however, that the Company shall not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged
untrue statement or omission or alleged omission made in the Registration Statement, the Base Prospectus, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing
Prospectus or any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, in reliance upon and in conformity with the Underwriter Information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each Underwriter, severally and not jointly, will indemnify and hold harmless the
Company against any losses, claims, damages or liabilities to which the Company may become subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an
untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, the Base Prospectus, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer
Free Writing Prospectus, or any roadshow or any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, or arise out of or are based upon the omission or alleged omission to state
therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged
omission was made in the Registration Statement, the Base Prospectus, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, or any roadshow or any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, in reliance upon and in conformity with the Underwriter Information; and will reimburse the Company for any legal or other expenses
reasonably incurred by the Company in connection with investigating or defending any such action or claim as such expenses are incurred. As used in this Agreement with respect to an Underwriter and an applicable document, &#8220;Underwriter
Information&#8221; shall mean the written information furnished to the Company by such Underwriter through the Representatives expressly for use therein; it being understood and agreed upon that the only such information furnished by any Underwriter
consists of the following information in the Prospectus furnished on behalf of each Underwriter: the concession and reallowance figures appearing in the fifth paragraph under the caption &#8220;Underwriting&#8221;, and the information contained in
the eighth, ninth and tenth paragraphs under the caption &#8220;Underwriting&#8221;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Promptly after receipt by an indemnified party
under subsection (a)&nbsp;or (b) above of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying party in
writing of the commencement thereof; provided that the failure to notify the indemnifying party shall not relieve it from any liability that it may have under the preceding paragraphs of this Section&nbsp;9 except to the extent that it has been
materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and provided further that the failure to notify the indemnifying party shall not relieve it from any liability that it may have to an indemnified party
otherwise than under the preceding paragraphs of this Section&nbsp;9. In case any such action shall be brought against any indemnified party and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be
entitled to participate therein and, to the extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party (who shall not, except
with the consent of the indemnified party, be counsel to the indemnifying party), and, after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party shall not be liable to
such indemnified party under such subsection for any legal expenses of other counsel or any other expenses, in each case subsequently incurred by such indemnified party, in connection with the defense thereof other than reasonable costs of
investigation. No indemnifying party shall, without the written consent of the indemnified party, effect the settlement or compromise of, or consent to the entry of any judgment with respect to, any pending or threatened action or claim in respect
of which indemnification or contribution may be sought hereunder (whether or not the indemnified party is an actual or potential party to such action or claim) unless such settlement, compromise or judgment (i)&nbsp;includes an unconditional release
of the indemnified party from all liability arising out of such action or claim and (ii)&nbsp;does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any indemnified party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) If the indemnification provided for in this Section&nbsp;9 is unavailable to or
insufficient to hold harmless an indemnified party under subsection (a)&nbsp;or (b) above in respect of any losses, claims, damages or liabilities (or actions in respect thereof) referred to therein, then each indemnifying party shall contribute to
the amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one
hand and the Underwriters on the other from the offering of the Shares. If, however, the allocation provided by the immediately preceding sentence is not permitted by applicable law, then each indemnifying party shall contribute to such amount paid
or payable by such indemnified party in such proportion as is appropriate to reflect not only such relative benefits but also the relative fault of the Company on the one hand and the Underwriters on the other in connection with the statements or
omissions which resulted in such losses, claims, damages or liabilities (or actions in respect thereof), as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on
the other shall be deemed to be in the same proportion as the total net proceeds from the offering (before deducting expenses) received by the Company bear to the total underwriting discounts and commissions received by the Underwriters, in each
case as set forth in the table on the cover page of the Prospectus. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to
state a material fact relates to information supplied by the Company on the one hand or the Underwriters on the other and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or
omission. The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this subsection (d)&nbsp;were determined by pro rata allocation (even if the Underwriters were treated as one entity for such
purpose) or by any other method of allocation which does not take account of the equitable considerations referred to above in this subsection (d). The amount paid or payable by an indemnified party as a result of the losses, claims, damages or
liabilities (or actions in respect thereof) referred to above in this subsection (d)&nbsp;shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such
action or claim. Notwithstanding the provisions of this subsection (d), no Underwriter shall be required to contribute any amount in excess of the amount by which the total price at which the Shares underwritten by it and distributed to the public
were offered to the public exceeds the amount of any damages which such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent
misrepresentation (within the meaning of Section&nbsp;11(f) of the Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#8217; obligations in this subsection (d)&nbsp;to
contribute are several in proportion to their respective underwriting obligations and not joint. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The obligations of the Company under
this Section&nbsp;9 shall be in addition to any liability which the Company may otherwise have and shall extend, upon the same terms and conditions, to each employee, officer and director of each Underwriter and each person, if any, who controls any
Underwriter within the meaning of the Act and each broker-dealer or other affiliate of any Underwriter; and the obligations of the Underwriters under this Section&nbsp;9 shall be in addition to any liability which the respective Underwriters may
otherwise have and shall extend, upon the same terms and conditions, to each officer and director of the Company (including any person who, with his or her consent, is named in the Registration Statement as about to become a director of the Company)
and to each person, if any, who controls the Company within the meaning of the Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10. (a) If any Underwriter shall default in its obligation to purchase the Shares which it
has agreed to purchase hereunder at a Time of Delivery, the Representatives may in the Representatives&#8217; discretion arrange for the Representatives or another party or other parties to purchase such Shares on the terms contained herein. If,
within <FONT STYLE="white-space:nowrap">thirty-six</FONT> hours after such default by any Underwriter, the Representatives do not arrange for the purchase of such Shares, then the Company shall be entitled to a further period of <FONT
STYLE="white-space:nowrap">thirty-six</FONT> hours within which to procure another party or other parties satisfactory to the Representatives to purchase such Shares on such terms. In the event that, within the respective prescribed periods, the
Representatives notify the Company that the Representatives have so arranged for the purchase of such Shares, or the Company notifies the Representative that they have so arranged for the purchase of such Shares, the Representatives or the Company
shall have the right to postpone such Time of Delivery for a period of not more than seven days, in order to effect whatever changes may thereby be made necessary in the Registration Statement or the Prospectus, or in any other documents or
arrangements, and the Company agrees to file promptly any amendments or supplements to the Registration Statement or the Prospectus which in your opinion may thereby be made necessary. The term &#8220;Underwriter&#8221; as used in this Agreement
shall include any person substituted under this Section with like effect as if such person had originally been a party to this Agreement with respect to such Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the
Representatives and the Company as provided in subsection (a)&nbsp;above, the aggregate number of such Shares which remains unpurchased does not exceed <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate number of all the Shares to
be purchased at such Time of Delivery, then the Company shall have the right to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter to purchase the number of shares which such Underwriter agreed to purchase hereunder at
such Time of Delivery and, in addition, to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter to purchase its pro rata share (based on the number of Shares which such Underwriter agreed to purchase hereunder) of the
Shares of such defaulting Underwriter or Underwriters for which such arrangements have not been made; but nothing herein shall relieve a defaulting Underwriter from liability for its default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by you and the
Company as provided in subsection (a)&nbsp;above, the aggregate number of such Shares which remains unpurchased exceeds <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate number of all the Shares to be purchased at such Time of
Delivery, or if the Company shall not exercise the right described in subsection (b)&nbsp;above to require <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters to purchase Shares of a defaulting Underwriter or Underwriters, then this
Agreement (or, with respect to the Second Time of Delivery, the obligations of the Underwriters to purchase and of the Company to sell the Optional Shares) shall thereupon terminate, without liability on the part of any <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter or the Company, except for the expenses to be borne by the Company and the Underwriters as provided in Section&nbsp;7 hereof and the indemnity and contribution agreements in Section&nbsp;9
hereof; but nothing herein shall relieve a defaulting Underwriter from liability for its default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11. The respective indemnities,
agreements, representations, warranties and other statements of the Company and the several Underwriters, as set forth in this Agreement or made by or on behalf of them, respectively, pursuant to this Agreement, shall remain in full force and
effect, regardless of any investigation (or any statement as to the results thereof) made by or on behalf of any Underwriter or any controlling person of any Underwriter, or the Company, or any officer or director or controlling person of the
Company, and shall survive delivery of and payment for the Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12. If this Agreement shall be terminated pursuant to Section&nbsp;10 hereof, the Company
shall not then be under any liability to any Underwriter except as provided in Sections&nbsp;7 and 9 hereof; but, if for any other reason, any Shares are not delivered by or on behalf of the Company as provided herein, the Company will reimburse the
Underwriters through the Representatives for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses approved in writing by the Representatives, including fees and disbursements of counsel,
reasonably incurred by the Underwriters in making preparations for the purchase, sale and delivery of the Shares not so delivered, but the Company shall then be under no further liability to any Underwriter except as provided in Sections 7 and 9
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13. In all dealings hereunder, you shall act on behalf of each of the Underwriters, and the parties hereto shall be entitled to
act and rely upon any statement, request, notice or agreement on behalf of any Underwriter made or given by you as the Representatives. All statements, requests, notices and agreements hereunder shall be in writing, and if to the Underwriters shall
be delivered or sent by mail, telex or facsimile transmission to you as the Representatives at: Goldman Sachs&nbsp;&amp; Co. LLC, 200 West Street, New York, New York 10282-2198, Attention: Registration Department, Leerink Partners LLC, 1301 Avenue
of the Americas, 5th Floor, New York, New York, 10019, Attention: Stuart R. Nayman, and Evercore Group L.L.C., 55 East 52nd Street, New York, NY 10055, Attention: ECM General Counsel; Barclays Capital Inc., 745 Seventh Avenue, New York, New York
10019, Attention: Syndicate Registration (fax: <FONT STYLE="white-space:nowrap">(646)&nbsp;834-8133);</FONT> and if to the Company shall be delivered or sent by mail, telex or facsimile transmission to the address of the Company set forth in the
Registration Statement, Attention: Secretary; provided, however, that any notice to an Underwriter pursuant to Section&nbsp;9(c) hereof shall be delivered or sent by mail, telex or facsimile transmission to such Underwriter at its address set forth
in its Underwriters&#8217; Questionnaire, or telex constituting such Questionnaire, which address will be supplied to the Company by you upon request. Any such statements, requests, notices or agreements shall take effect upon receipt thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. <FONT STYLE="white-space:nowrap">107-56</FONT> (signed into
law October&nbsp;26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company, which information may include the name and address of their respective clients, as
well as other information that will allow the Underwriters to properly identify their respective clients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14. This Agreement shall be
binding upon, and inure solely to the benefit of, the Underwriters, the Company and, to the extent provided in Sections 9 and 11 hereof, the officers and directors of the Company and each person who controls the Company or any Underwriter, and their
respective heirs, executors, administrators, successors and assigns, and no other person shall acquire or have any right under or by virtue of this Agreement. No purchaser of any of the Shares from any Underwriter shall be deemed a successor or
assign by reason merely of such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15. Time shall be of the essence of this Agreement. As used herein, the term &#8220;business
day&#8221; shall mean any day when the Commission&#8217;s office in Washington, D.C. is open for business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">16. The Company acknowledges
and agrees that (i)&nbsp;the purchase and sale of the Shares pursuant to this Agreement is an <FONT STYLE="white-space:nowrap">arm&#8217;s-length</FONT> commercial transaction between the Company, on the one hand, and the several Underwriters, on
the other, (ii)&nbsp;in connection therewith and with the process leading to such transaction each Underwriter is acting solely as a principal and not the agent or fiduciary of the Company, (iii)&nbsp;no Underwriter has assumed an advisory or
fiduciary responsibility in favor of the Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on other matters) or any
other obligation to the Company except the obligations expressly set forth in this Agreement and (iv)&nbsp;the Company has consulted its own legal and financial advisors to the extent it deemed appropriate. The Company agrees that it will not claim
that the Underwriters, or any of them, has rendered advisory services of any nature or respect, or owes a fiduciary or similar duty to the Company, in connection with such transaction or the process leading thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">17. This Agreement supersedes all prior agreements and understandings (whether written or
oral) between the Company and the Underwriters, or any of them, with respect to the subject matter hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">18. <B>This Agreement and any
transaction contemplated by this Agreement shall be governed by and construed in accordance with the laws of the State of New York without regard to principles of conflict of laws that would result in the application of any other law than the laws
of the State of New York. The Company agrees that any suit or proceeding arising in respect of this Agreement or any transaction contemplated by this Agreement will be tried exclusively in the U.S. District Court for the Southern District of New
York or, if that court does not have subject matter jurisdiction, in any state court located in The City and County of New York and the Company agrees to submit to the jurisdiction of, and to venue in, such courts.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">19. The Company and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right
to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">20. This
Agreement may be executed by any one or more of the parties hereto in any number of counterparts, each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">21. The words &#8220;execution,&#8221; &#8220;execute&#8221;, &#8220;signed,&#8221; &#8220;sign,&#8221; &#8220;signature,&#8221; and words of
like import in or related to any document to be signed in connection with this Agreement and the transactions contemplated hereby shall be deemed to include electronic signatures, or the keeping of records in electronic form, each of which shall be
of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic
Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">22. Recognition of the U.S. Special Resolution Regimes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the
transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any
such interest and obligation, were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event that any
Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted
to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) As used in this section: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;BHC Act Affiliate&#8221; has the meaning assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted in
accordance with, 12 U.S.C. &#167; 1841(k). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Covered Entity&#8221; means any of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a &#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;
252.82(b); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a &#8220;covered bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;
47.3(b); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a &#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;
382.2(b). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Default Right&#8221; has the meaning assigned to that term in, and shall be interpreted
in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;U.S. Special Resolution
Regime&#8221; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding, please sign and return to us an
executed facsimile or executed scanned copy of this Agreement and such delivery hereof shall constitute a binding agreement between each of the Underwriters and the Company. It is understood that your acceptance of this letter on behalf of each of
the Underwriters is pursuant to the authority set forth in a form of Agreement among Underwriters, the form of which shall be submitted to the Company for examination upon request, but without warranty on your part as to the authority of the signers
thereof. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>Vir Biotechnology, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jason O&#8217;Byrne</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Jason O&#8217;Byrne</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">Title:&#8201;&#8202;Executive Vice President and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">&#8195;&#8201;&#8195;&#8201;Chief Financial Officer</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Underwriting Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Accepted as of the date hereof:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Goldman Sachs&nbsp;&amp; Co. LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Lyla Bibi Maduri</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Lyla Bibi Maduri</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Leerink Partners LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Liz Meeks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Liz Meeks</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Senior Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Evercore Group L.L.C.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gloria Tang</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Gloria Tang</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Barclays Capital Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dan Cocks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Dan Cocks</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">On behalf of each of the Underwriters</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Underwriting Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE I </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Number<BR>of Firm<BR>Shares to be<BR>Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Optional<BR>Shares to be</B><br><B>Purchased if</B><br><B>Maximum Option</B><br><B>Exercised</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,705,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,005,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,117,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">767,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,058,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">608,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Barclays Capital Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,764,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">264,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,647,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,647,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Issuer Free Writing Prospectuses not included in the Pricing Disclosure Package: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">None </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Additional Documents Incorporated by
Reference: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">None </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Information other than
the Pricing Prospectus that comprise the Pricing Disclosure Package: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The public offering price per share for the Shares is $8.50 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The number of Firm Shares purchased by the Underwriters is 17,647,059 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">None </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>ANNEX I </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Vir Biotechnology, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>__________, 2026 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman
Sachs&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evercore
Group L.L.C. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Barclays Capital Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As representatives of
the several Underwriters </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">named in Schedule I to the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Underwriting Agreement referred to below </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o
Goldman Sachs&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 West Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York,
NY 10282-2198 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Leerink Partners LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1301 Avenue of the
Americas, 5th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Evercore Group
L.L.C. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">55 East 52nd Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10055 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Barclays Capital Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">754 Seventh Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Re: <U>Vir Biotechnology,
Inc. &#8211; <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The undersigned understands that you, as representatives (the &#8220;Representatives&#8221;), propose to enter into an underwriting agreement
(the &#8220;Underwriting Agreement&#8221;) on behalf of the several underwriters named in Schedule I to such agreement (collectively, the &#8220;Underwriters&#8221;), with Vir Biotechnology, Inc., a Delaware corporation (the &#8220;Company&#8221;),
providing for a public offering (the &#8220;Public Offering&#8221;) of shares of common stock, par value $0.0001 per share (the&nbsp;&#8220;Common Stock&#8221;), of the Company (the &#8220;Shares&#8221;) pursuant to a Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-275314)</FONT> (the &#8220;Registration Statement&#8221;) filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In consideration of the agreement by the Underwriters to offer and sell the Shares, and of
other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned agrees that, during the period beginning from the date of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and
continuing to and including the date 60 days after the date set forth on the final prospectus supplement used to sell the Shares (the <FONT STYLE="white-space:nowrap">&#8220;Lock-Up</FONT> Period&#8221;), the undersigned shall not, and shall not
cause or direct any of its affiliates to, (i)&nbsp;offer, sell, contract to sell, pledge, grant any option to purchase, lend or otherwise dispose of any shares of Common Stock of the Company, or any options or warrants to purchase any shares of
Common Stock of the Company, or any securities convertible into, exchangeable for or that represent the right to receive shares of Common Stock of the Company (such options, warrants or other securities together with the Common Stock, <FONT
STYLE="white-space:nowrap">&#8220;Lock-Up</FONT> Securities&#8221;), including without limitation any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities now owned or hereafter acquired by the undersigned, or publicly disclose the intention
to make any offer, sale, pledge or other disposition or (ii)&nbsp;engage in any hedging or other transaction or arrangement (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or
combination thereof, forward, swap, or any other derivative transaction or instrument, however described or defined) which is designed to or which reasonably could be expected to lead to or result in a sale or disposition (whether by the undersigned
or someone other than the undersigned), or transfer of any of the economic consequences of ownership, in whole or in part, directly or indirectly, of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such transaction or
arrangement (or instrument provided for thereunder) would be settled by delivery of Common Stock or other securities, in cash or otherwise (any such sale, disposition or transfer of economic consequences as described in this clause (ii),
&#8220;Prohibited Activity&#8221;). The undersigned represents and warrants that the undersigned is not, and has not caused or directed any of its affiliates to be or become, currently a party to any agreement or arrangement that is designed to or
which reasonably could be expected to lead to or result in any Prohibited Activity during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If the undersigned is not a natural person, the undersigned represents and warrants that no single natural person, entity or
&#8220;group&#8221; (within the meaning of <FONT STYLE="white-space:nowrap">Section&nbsp;13d-3</FONT> of the Securities Exchange Act of 1934, as amended, the &#8220;Exchange Act&#8221;) beneficially owns, directly or indirectly, 50% or more of the
common equity interests, or 50% or more of the voting power, in the undersigned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the undersigned may
transfer or otherwise dispose of the undersigned&#8217;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities (collectively, the &#8220;Undersigned&#8217;s Shares&#8221;): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as a <I>bona fide</I> gift or gifts, provided that the donee or donees thereof agree to be bound in writing by
the restrictions set forth herein, provided that any required filing under Section&nbsp;16 of the Exchange Act shall indicate in the footnotes thereto that the filing relates to the applicable circumstances described in this clause, and no other
public announcement shall be required or shall be made voluntarily in connection with such transfer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any trust for the direct or indirect benefit of the undersigned or the immediate family (as defined below)
of the undersigned, or if the undersigned is a trust, to a trustor, trustee (or <FONT STYLE="white-space:nowrap">co-trustee)</FONT> or beneficiary of the trust or to the estate of the beneficiary of such trust, provided that the transferee agrees to
be bound in writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a transfer for value; and provided further that any required filing under Section&nbsp;16 of the Exchange Act shall indicate in
the footnotes thereto that the filing relates to the applicable circumstances described in this clause, and no other public announcement shall be required or shall be made voluntarily in connection with such transfer; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in connection with the sale of any of the Undersigned&#8217;s Shares acquired (a)&nbsp;in the Public Offering
or (b)&nbsp;in open market transactions after the Public Offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the undersigned is a corporation, partnership, limited liability company, trust or other business entity
(a)&nbsp;to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned or the immediate family
of the undersigned, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control with the undersigned or affiliates or immediate family of the undersigned (including, for the avoidance of
doubt, where the undersigned is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (b)&nbsp;as part of a distribution, transfer or disposition without consideration by the
undersigned to its stockholders, partners, members, beneficiaries or other equity holders; provided, however, that in the case of any transfer or disposition contemplated by (a)&nbsp;or (b) above, it shall be a condition to the transfer or
disposition that the transferee agrees to be bound in writing by the restrictions set forth herein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">v.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the Company in connection with the exercise or settlement of options, warrants or other rights to acquire
shares of Common Stock or any securities convertible into, exercisable or exchangeable for or that represent the right to receive shares of Common Stock in accordance with their terms (including the vesting or settlement of restricted stock units
and including, in each case, by way of net exercise and/or to cover withholding tax obligations in connection with such exercise, vesting or settlement) pursuant to an employee benefit plan, option, warrant or other right disclosed in the final
prospectus supplement for the Public Offering (including the documents incorporated by reference therein), provided that any such shares issued upon exercise, vesting or settlement, as applicable, of such option, warrant, restricted stock unit or
other right shall be subject to the restrictions set forth herein, and provided further that any filing under Section&nbsp;16 of the Exchange Act shall indicate in the footnotes thereto that the filing relates to the applicable circumstances
described in this clause, and no other public announcement shall be required or shall be made voluntarily in connection with such transfer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">vi.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by will or intestacy, provided that the transferee agrees to be bound in writing by the restrictions set forth
herein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">vii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any immediate family member of the undersigned, provided that such family member agrees to be bound by the
restrictions set forth herein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">viii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the Company pursuant to agreements under which the Company has (a)&nbsp;the option to repurchase such shares
upon termination of service of the undersigned or (b)&nbsp;a right of first refusal with respect to transfers of such shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ix.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pursuant to a court order or settlement agreement related to the distribution of assets in connection with the
dissolution of a marriage, domestic partnership or civil union; provided that any required filing under Section&nbsp;16 of the Exchange Act shall indicate in the footnotes thereto that the filing relates to the circumstances described in this clause
and no other public announcement shall be required or shall be made voluntarily by the undersigned in connection with such transfer or disposition; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">x.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pursuant to a trading plan that complies with Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the
Exchange Act <FONT STYLE="white-space:nowrap">(&#8220;10b5-1</FONT> Trading Plan&#8221;) that is existing as of the date hereof, provided that to the extent a public announcement or filing under the Exchange Act is required of the undersigned or the
Company regarding the sale, such announcement or filing shall include a statement to the effect that the sale occurred pursuant to such <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">xi.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">with the prior written consent of Goldman Sachs&nbsp;&amp; Co. LLC and Leerink Partners LLC on behalf of the
Underwriters; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">xii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pursuant to the sale on the open market of Common Stock underlying restricted stock units held by the
undersigned that will vest during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period and settle during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, but solely to the extent necessary to satisfy income tax withholding and
remittance obligations in connection with the vesting and settlement of such restricted stock units that are outstanding as of the date of the final prospectus supplement for the Public Offering and described therein and pursuant to an equity
incentive plan or other equity award plan described in the final prospectus supplement for the Public Offering or in a document incorporated therein by reference; <I>provided</I>&nbsp;that (a)&nbsp;any remaining shares of Common Stock issued upon
vesting of such restricted stock units shall be subject to the restrictions set forth in <FONT STYLE="white-space:nowrap">this&nbsp;Lock-Up&nbsp;Agreement,</FONT> (b)&nbsp;any filing under Section&nbsp;16 of the Exchange Act required in connection
therewith shall indicate that such transfer is to satisfy income tax withholding and remittance obligations in connection with the vesting and settlement of restricted stock units and (c)&nbsp;no filing or public announcement shall be voluntarily
made during <FONT STYLE="white-space:nowrap">the&nbsp;Lock-Up&nbsp;Period.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For purposes of this <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, &#8220;immediate family&#8221; shall mean any relationship by blood, marriage, domestic partnership, civil union or adoption, not more remote than first cousin. Notwithstanding anything to the
contrary, in the case of clauses (iii), (iv), (vii) and (viii)(b) above, no filing under the Exchange Act or any other public filing or disclosure of such transfer by or on behalf of the undersigned shall be required or voluntarily made during the <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Period (other than a filing on a Form 5 after the expiration of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period and other than a filing under Section&nbsp;13 of the Exchange Act). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Furthermore, notwithstanding the restrictions imposed by this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, the undersigned may
exercise an option or other equity award to purchase shares of Common Stock or exercise warrants (pursuant to an employee benefit plan, option, warrant or other right disclosed in the final prospectus supplement for the Public Offering (including
the documents incorporated by reference therein)) on a cash basis, provided that any such shares issued upon such exercise shall be subject to the restrictions set forth herein, and provided further that any filing under Section&nbsp;16 of the
Exchange Act shall indicate in the footnotes thereto that the filing relates to the applicable circumstances described in this paragraph, and no other public announcement shall be required or shall be made voluntarily in connection with such
exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Further, this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement shall not restrict any sale, disposal or transfer of
the Undersigned&#8217;s Shares to a <I>bona fide</I> third party pursuant to a tender offer for securities of the Company or any merger, consolidation or other business combination involving a Change of Control (as defined below) of the Company
occurring after the settlement of the Public Offering, that, in each case, has been approved by the board of directors of the Company; provided that all of the Undersigned&#8217;s Shares subject to this
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement that are not so transferred, sold, tendered or otherwise disposed of remain subject to this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement; and provided, further, that it shall be
a condition of transfer, sale, tender or other disposition that if such tender offer or other transaction is not completed, any of the Undersigned&#8217;s Shares subject to this Lock-</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Up Agreement shall remain subject to the restrictions on transfer set forth herein. For the purposes of this paragraph, &#8220;Change of Control&#8221; means the consummation of any <I>bona
fide</I> third party tender offer, merger, consolidation or other similar transaction, the result of which is that any &#8220;person&#8221; (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Exchange Act), or group of persons,
other than the Company or its subsidiaries, becomes the beneficial owner (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> and <FONT STYLE="white-space:nowrap">13d-5</FONT> of the Exchange Act) of at least 50% of the total voting
power of the voting share capital of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Additionally, the undersigned may establish or amend a
<FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan for the transfer of the Undersigned&#8217;s Shares, provided that such <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan does not provide for any transfers of Common Stock during
the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, no filing under the Exchange Act nor any other public filing or disclosure of such <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan shall be voluntarily made during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period, and to the extent a filing under the Exchange Act or other public filing is legally required by or on behalf of the undersigned or the Company regarding the establishment of such <FONT
STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan, such filing shall include a statement to the effect that no transfer of Common Stock may be made under such <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The undersigned now has, and, except as contemplated above, for the duration of this <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement will have, good and marketable title to the Undersigned&#8217;s Shares, free and clear of all liens, encumbrances, and claims whatsoever. The undersigned also agrees and consents to the entry of
stop transfer instructions with the Company&#8217;s transfer agent and registrar against the transfer of the Undersigned&#8217;s Shares except in compliance with the foregoing restrictions. The undersigned hereby waives any and all notice
requirements and rights with respect to the registration of securities pursuant to any agreement, understanding or anything otherwise setting forth the terms of any security of the Company held by the undersigned, including any registration rights
agreement or investors&#8217; rights agreement to which the undersigned and the Company may be party; provided, however, that such waiver shall apply only to the proposed Public Offering, and any other action taken by the Company in connection with
the proposed Public Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement (and for the avoidance of doubt, the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period described herein) and related restrictions shall automatically terminate upon the earliest to occur, if any, of (i)&nbsp;the Company advising the Representatives in writing prior to the execution of
the Underwriting Agreement that it has determined not to proceed with the Public Offering, (ii)&nbsp;the termination of the Underwriting Agreement before the sale of any Shares to the Underwriters, or (iii)&nbsp;March&nbsp;31, 2026, in the event the
closing of the Public Offering shall not have occurred on or before such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreement and any claim, controversy or dispute arising under or related to this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the
conflict of laws principles thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The undersigned understands that the Company and the Underwriters are relying upon this <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement in proceeding toward consummation of the Public Offering. The undersigned further understands that this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement is irrevocable and shall be binding
upon the undersigned&#8217;s heirs, legal representatives, successors, and assigns. This <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying
with the U.S. federal ESIGN Act of 2000, <I>e.g.</I>, www.docusign.com or www.echosign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all
purposes. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>IF AN INDIVIDUAL:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[Name of Undersigned <I>(Print exact name</I>)]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>IF NOT SIGNING IN AN INDIVIDUAL CAPACITY: </B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[Name of Undersigned <I>(Print exact name</I>)]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[Name of Authorized Signatory <I>(Print full name</I>)]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title of Authorized Signatory <I>(Print full title</I>)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><I>(indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity)</I></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d85338dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g85338dsp044.jpg" ALT="LOGO" STYLE="width:6.04653in;height:0.879167in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">February&nbsp;25, 2026 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vir Biotechnology, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1800 Owens Street, Suite 900 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94158 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You have requested our opinion with respect to certain matters in connection with the sale and issuance by Vir Biotechnology, Inc., a Delaware
corporation (the &#8220;<B><I>Company</I></B>&#8221;), of up to an aggregate of 20,294,117 of shares (the &#8220;<B><I>Shares</I></B>&#8221;) of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;<B><I>Common
Stock</I></B>&#8221;), including up to an aggregate of 2,647,058 shares that may be sold pursuant to the exercise of an option granted by the Company to the underwriters, pursuant to (i)&nbsp;a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3ASR</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-275314)</FONT> (the &#8220;<B><I>Registration Statement</I></B>&#8221;) filed with the Securities and Exchange Commission (the
&#8220;<B><I>Commission</I></B>&#8221;) under the Securities Act of 1933, as amended (the &#8220;<B><I>Act</I></B>&#8221;), which became automatically effective upon its filing on November&nbsp;3, 2023, the prospectus included therein dated
November&nbsp;3, 2023 (the &#8220;<B><I>Base Prospectus</I></B>&#8221;), as supplemented by the prospectus supplement, dated February&nbsp;25, 2026, filed with the Commission pursuant to Rule 424(b) under the Act (the &#8220;<B><I>Prospectus
Supplement</I></B>&#8221; and together with the Base Prospectus, the &#8220;<B><I>Prospectus</I></B>&#8221;) and (ii)&nbsp;an underwriting agreement, dated February&nbsp;25, 2026, and entered into by and among the Company and Goldman
Sachs&nbsp;&amp; Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc., as representatives of the several underwriters named therein (the &#8220;<B><I>Underwriting Agreement</I></B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this opinion, we have examined and relied upon the Registration Statement, the Prospectus, the Company&#8217;s Amended and
Restated Certificate of Incorporation and Amended and Restated Bylaws, as currently in effect, and the originals or copies certified to our satisfaction of such other documents, records, certificates, memoranda and other instruments as in our
judgment are necessary or appropriate to enable us to render the opinion expressed below. With your consent, we have relied upon certificates and other assurances of officers of the Company as to factual matters without having independently verified
such factual matters.&nbsp;We have assumed the genuineness and authenticity of all documents submitted to us as originals, and the conformity to originals of all documents submitted to us as copies thereof and the due execution and delivery of all
documents where due execution and delivery are a prerequisite to the effectiveness thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is being furnished in connection
with the requirements of Item 601(b)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the Prospectus, other
than as expressly stated herein with respect to the issue of the Shares. Our opinion is limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated. Our opinion herein is expressed solely
with respect to the federal laws of the United States and the General Corporation Law of the State of Delaware (the &#8220;<B><I>DGCL</I></B>&#8221;). Our opinion is based on these laws as in effect on the date hereof, and we disclaim any obligation
to advise you of facts, circumstances, events or developments which hereafter may be brought to our attention and which may alter, affect or modify the opinion expressed herein. We are not rendering any opinion as to compliance with any federal or
state antifraud law, rule or regulation relating to securities, or to the sale or issuance thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g85338dsp44a.jpg" ALT="LOGO" STYLE="width:7.65347in;height:0.688194in;">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the foregoing and the other matters set forth herein, it is our opinion that,
when the Shares to be issued and sold by the Company are issued and paid for in accordance with the terms of the Underwriting Agreement, such Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have
assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
consent to the reference to our firm under the caption &#8220;Legal Matters&#8221; included in the Prospectus and to the filing of this opinion as an exhibit to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> of the Company. In
giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules and regulations of the Commission thereunder. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sincerely,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Gunderson Dettmer Stough Villeneuve Franklin&nbsp;&amp; Hachigian, LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GUNDERSON DETTMER STOUGH</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">VILLENEUVE FRANKLIN&nbsp;&amp; HACHIGIAN, LLP</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g85338dsp44a.jpg" ALT="LOGO">
 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>vir-20260225.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release merge Build:20260112.3 -->
<!-- Creation date: 2/27/2026 1:03:34 AM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:vir="http://www.vir.bio/20260225"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.vir.bio/20260225"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vir-20260225_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vir-20260225_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>vir-20260225_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release merge Build:20260112.3 -->
<!-- Creation date: 2/27/2026 1:03:34 AM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>vir-20260225_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release merge Build:20260112.3 -->
<!-- Creation date: 2/27/2026 1:03:34 AM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="vir-20260225.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g85338dsp044.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g85338dsp044.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !3 CP# 1$  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H \Z\=>*]8\,^-=&,TTEGX
M5F40M<6T4<I:[9B$CF#'>D9&,,@/S?>(&*VC%2B^YE)M278XO0/C+K^H_"?Q
M+K\TMM_:=A8V%Q!B(!=TUE;S/E>XWRO^%:.FE-1]?S(4VXMEV;XC>(IO#)\2
MQZM;VRWVK_V/#ISVZ&'3@;KR!+*WWVD 4G!(4M(@VXZKDC?EMYCYI6O<S_$'
MQ9\6>$O%D&C120>([73]5"7MRD"K-/9FQDN)(P%POGQ[ _& RL@(&22U3C)7
MV_X<3G*+MN$?QVU:R\ >%?%LGV;4K#6[:^AMUB3:+B]WL;&-#_TU"LOUQZT>
MR3DX]OZ8>T?*I=_Z10;X[^(=/U3Q187$L<T=G82PZ??FQ>.*>]M%B%T5<C8^
MYWG&Q2=OV5O6J]E&R?\ 6O\ 7XB]HU<]0MO&=Y+\1[[13+#]AB\/6VI1@ ;C
M,\TZ-SW&(UXK#E7+?S->9\UO(\Q\.?%#QZWPT\)>))HKJYNM?6VM#;ZFEE&%
MGNHD,,\)MW;]TLC<K)A]IY&16[A#G<>WKT,E.7*GW/H.TCEBM(4N)1/.J*LD
MH7:'8#EL=LGG%<C.DFI % !0 4 >0:M\4=7MH]=MHI;:&<>+8O#]O=R("EI"
M\$,GFN,C<078#/&67.0,'H4%IZ7,7-Z^MC*UGXB^*=%.M13Z@9]$\.:FT&IZ
M[8VT+W(M_LL,ZLT+85@IE99/+!;"J54$G%*$7;NR7*2OY&O\3OC!=^#_ (A^
M&-*M!NTHO')K,WV6298XIW\F']XH*Q'S"I^<@$$U,*:E%M_(J<^622.$U']H
M_P 2>&[0QZC:6TM]]MU2>T*H5CO;""WO&7D?=>*:"-9,?PM&W_+3 U5&+V\O
MOT,W5:W\_P!3<\5_$?Q#HMY9Z!8:SJ>N:W-J,"7#6%C91-Y,D#R#[,9F$10E
M>KL6 &,FIC"+]YJR^94I-:)ZFCXE^)GB"R\(>)9;221M2LO$MGH]NL$=N;DQ
M2M:A@!(PB,G[Y\%B%SCG J8PBY+TO^8W)I/U-;3O%?B'3?&F@6>OS7UGI.H1
M);V9EAM9'N+HQR.\5T86;RW C9E,?[LA3EL\5+C%Q;CN-2::3/5:P-@H Y3Q
MO\5?"/PVDLX_$^OV>BO>!V@6Z8CS N-V..VX?G6].A4K7]G&]C"K7I4;>TE:
MYS'_  U%\*/^AZTG_OX?\*V^I8C^1F'U[#?SH/\ AJ+X4?\ 0]:3_P!_#_A1
M]2Q'\C#Z]AOYT'_#47PH_P"AZTG_ +^'_"CZEB/Y&'U[#?SHDMOVF?A;>W,-
MO!XWTJ2:9Q'&BR'+,3@ <=R:'@L0E=P8UC<,W931Z=7$=H4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M=A'!KHN-8TB5X&L7:T00EI4^[N;@ ]<$5M1FH0F_0RJQ<Y17J=1^R3I<^@_
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M&K,Q4_O-K+N8!E//8%:"@UR]5<*<W)._0]:KG-@H * "@ H * "@ H * "@
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M'>?29?$QOPVF+*L'V*<1C$A4MNRIS]P5VX?%U,+=4[:G#B<'2Q33J7T/-O\
MAWK\*O[VN_\ @<O_ ,;KL_M;$>7W'%_9&&\_O#_AWK\*O[VN_P#@<O\ \;H_
MM;$>7W!_9&&\_O#_ (=Z_"K^]KO_ ('+_P#&Z/[6Q'E]P?V1AO/[RUIG[ OP
MPTG4K2^@?6_/MI5F3=>J1N4@C(V=.*4LTQ$DT[?<..4X>+35]/,^D*\<]H*
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M;JUMH-/2UAFF:TL9'5F=9#\TIEQ"?D7Y"K$'*DY'!4IQ@KH<)RDSVZN4W"@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M][[T8?8WWV^\#UINI)JS!02=T=76984 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
0 !0 4 % !0 4 % !0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g85338dsp44a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g85338dsp44a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !! M0# 1$  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z "@ H
M* "@ H * "@ H * $)Q0 ;J #=0 ;J #=0 ;J #=0 ;J #=0 ;J #=0 ;J #
M=0 ;J #=0 ;J #=0 ;J #=0 ;J #=0 ;J #=0 ;J #=0 ;J #=0 ;J #=0 ;
MJ #=0 ;J #=0 ;J #=0 ;J #=0 ;J #=0 ;J #=0 ;J #=0 ;J #=0 ;J #=
M0 ;J #=0 ;J #=0 ;J #=0 ;J #=0 ;J #=0 ;J #=0 ;J #=0 ;J #=0 ;J
M #=0 ;J #=0 ;J #=0 ;J #K0 M !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 UNM "4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 =: "@ H
M * "@ H * #% !B@ H * "@ H * "@ H * #- !0 4 % !TH * "@ [4 '2@
M H * #- !0 4 % !0 4 % !0 4 % !0 9H #Q0 4 % !0 4 % !0 4 % !0
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MFP4 % !0 4 % !0 4 % !0 4 % !0 X=* %H * "@ H * "@ H * "@ H *
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M7,$JO&,?>RP..._I2::=F/3='&Z?\=?".K>')]<L;NYO+!-6.B1>1:N\EU=
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MKF&ZM\LC/#('3(X8$CC(Y!%2TUN,S;#6_#ECH0DL]0TN#1K,"W#PSQK;P 8
M3(.U<<#%4U*^NXKJQ-)XGT*$9DU;3D"PBYRUS&,1$\2=?N_[72E9]@NBW9ZQ
M8:A++%:WMO<RQ!6D2&579 PRI(!XR.1GK2::"Y;H&% !0 4 % !0 4 % !0
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M7DO[.:'4[2PDFDT[69FDC*RR6CQF.!PJ.=_[UBS -O Y[U5BK)W?Z?,Y^1]
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MTC1M/%L62:!+.$HX="FT[W9GW;L\X(KFJU?:02ZW;^\VA3Y)-^GX'NU<QL%
M!0 4 % !0 4 % !0 4 % !0 4 .'2@!: "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@!* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #%
M !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &!Z4 &!0
M 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* # H ,4 &!0 8
MH ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,4 &* #% !B@ Q0 8H ,
M4 +0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MF_\ %_D>/B_XR]"N>]/J2_X2]3L/&O\ R"-&_P!S_P!E6N#"_',Z<1\$"IX
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M^NX_] -5E?\ 'GZ?J.C\3*OP?_Y*]!_UYR?^@5IBO]Q?K^I69_PW\CU/6?\
MD&^-/^OC_P!H+7B4_CI_UU/.C_RY_P /ZL\[^"/_ "+-[_U\G_T!:]7-?XT?
M0[JWQ(S_ (6?\EDM/^N$G_H!K;$?[@_7]2\S_AOY&!?_ /)0/%7_ %^3_P#H
MUJZ*G^[4O1?D=F"_AKT0[PE_R+FK?]>=Q_*HK_[S#U153^$O4[7X8_\ (FV7
B^_)_Z$:ZJWQLTAL<C#]Z?_KO+_Z,:N"O_$?R_(Z:?PG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 25, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001706431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 25,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Vir Biotechnology, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-2730369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1800 Owens Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(415)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">906-4324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VIR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d85338d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d85338d8k.htm">d85338d8k.htm</File>
    <File>vir-20260225.xsd</File>
    <File>vir-20260225_lab.xml</File>
    <File>vir-20260225_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d85338d8k.htm": {
   "nsprefix": "vir",
   "nsuri": "http://www.vir.bio/20260225",
   "dts": {
    "inline": {
     "local": [
      "d85338d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "vir-20260225.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "vir-20260225_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vir-20260225_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2026-02-25_to_2026-02-25",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d85338d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2026-02-25_to_2026-02-25",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d85338d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.vir.bio//20260225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-26-077416-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-077416-xbrl.zip
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MI\;YDKDE!RNL'RS_\L'\>*A$QT7HABQ.@W1!1!G)_\.J9GGRW*4#[HRK#WS
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M _D-)JJP7%4G!@' !EHB%^84 $W \W$&:6 5:":7RJLC,BD8Q 9U3.. @"T
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MWSI>G4_R3N.W=^_CG4V[U1L%7SZ.JWNB]76K0O-G\K8^&AN'X9S,X3%K ,L
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M],[-26[0":]OE>;9'+Y;K>RT][)BDB_I(*WY5+U<+,@N;48PLSRA^**,5@1
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M4IVO(H/370)#H[R3/,$KA@M'OF#%W@68'SFFTR7J59JE)'?H&HMQ52[SJ>;
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MB)40" #^^-=R>LXZBU+^,2'6*-WO 6MZ! <@ ^>@(WGWRBE9.7CTPR#)90L
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M&N%7U?(\.I5PA<S=53:_.O6N#7XKC O(L_$IORYAA6'[JTN*)>L#?OWU@PW
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MAURZ$C^-,O0?=^/&CD81!;S[CVM6P4[+ 4TUNY#>#+2R%3>O9WI5NQ$,"=\
MV#=<!$6Y;. 99$ Q(^>R,&2 R]HQD?!?F?@]=6W?:W+/94Z<]B@Q@].*0+()
M('2*&-LUAZ9N0ATLN9/IDI4[FBBSE;$GE0!%^;F0-F!*F#76WHX-MDHO,Y#=
M9)T8@R0,H+AH(TG0FXCV]6&_(08_3;ASZ'E#4#T74]?!&C5HK"U6Z]A!P >[
M>ZRIQ0H2@65_Q6OL%UB%!XMQ$BIJ\QI<?'NU>Z-5,*[6Y7[EZ!KT:RZTKKY4
MWS<H.MD^P[&<6_*9/,F[F'\VG3CL'3J* ;-)IF_V%YL =Y_L.3\/H',L4&Z3
M["+>K(I1EE"R[-+G"4TII10;\J&7PE6V'BAN4Z +)+6H":7W0Z.%?XGCP(@5
M0O'TWQ1/I)H)AE3*CY-RL:JR\POW'3R9E1I6PJV*YY[4P9*[%G(?P-O'LG ^
MAARN*VF;)VN@Z42J:O (%Y_/TL2SUKFZ%L?BU*.WY3724.4K%23[OQ#5)E>'
M\!T(X&6W,^4!P]*N^#M9<9]=N-DAWDP4%%#W= U!0Z(0  )\,(M(,[7[$Y\O
M]5=[IQ9H4HZ4X:Z"(@.!@<@!_($?PT&7:KK/7C ?D++J9@9[7Q0I25M[X:B8
M<3L4):Z[.Y=;=ZVTL09>-8HXH+V(:!,7/^H(:CKY=F%%E?7.+XA$%QO)/7=W
MVL2:,AR)>H2#$1!,OSAH;8^.5@+5KBR[+2 YRM5/\FF&7U.XY4J(YO W&_,>
MDW*?OJ"9#V7<[#\7+'%@K;/&!:'P-2R::7(28A85W/>4 ^&?X9WM(8)="ZUQ
M[4*'BM(I]H75*Y[J_;EO(#FYP,K@XKS%:ZOOHO+-@;.IKK;L(:<BU]W7$]_7
MJ?U:6C REYPN<^9M#>HFW7!^,=[ENBTY=@BZMCW'>0W;CEXLGKFG.Q3";@9#
MDQD31\N%P.&\XRC5HCI:5V-=.17Z=10@V_(!LXG.I&7%I3XZ+#U^6?W'"-T5
M]6^U?ZC\C>X/5;^/5/*+N S'7V\^>%TC?_ FDQ+X9B.)1]\CB3=#H[+7D)K.
M5*Z9.QT9'ZZV<7 V\OIEM4.:K='"#'0TK*7J,7+QNZ\#YG:2_00F:FE1E_"O
M86H)>XJ#V5#E,G>1W3L:Q1'V'27]^4 DXABDPM4V6)QNO'6#!GJ.;^SH:/9P
M^Z^TV]C-T+%PQ]T'UVV]\(.Z7IRL>S<<B',B9>L[#]T^HFWD2AN.##YNR'[D
MB#>"K*$FZF;=D\4(&/#);;LNI(&J [ "QX!MF)(9#6>BW"Q%QI><XC9#77]$
M9KN*\#'QCS#S;EJI1:H5=7Y )WATM3X^]QEOS?IBO 2-=H-^HMB75WL4&>DW
MU=:T(ND_J;X3C&.T\D=/DM#DW2=%X($[?QNS#2 Q.:G6.ENR\2V$@W.JJ1J;
M[SD2S]><W^7PSK E&=L(T/!V%.V%]U=!HIY38R1,3T)A4H"C9T@$'$&P<#-G
MBB&HRV4U$<<#CG-&3AG'LO%*I(II3\%"4J!W5M0P]:6&FES5$NM5:H6\K <W
M?M ^C%P5G L14$O5JO'HZZMNCUF;*,;0-T8U0@H%UT("'XE](^);FJDCFZ(_
MDA^!1I2RV7F";?B*CG; -+[S6M.+BZ]=:TJ9"PY:<8:E&]5R&TIV_!J5W[G[
M;$IW>YJL<1KP^HBIBY)CBUX7IOD49XA@L_*55"Z$::F3;?J!I,[/=_0H*)GX
MFMME"76P3[UP @$-B03Q1)PP\LD3&0(1$[^3U89/?%2/03M:$/F#A*/^^/#N
MX^\NQ=F3\^F,[J0#2^]K7<FZL,5EZ^TL#431Z^4*IU4J-/G^4Y'_$+[5ZM8%
M:'2D5Z&/D'7 4DS.6<]4W&4,*U0VHDQ(BU-F-E%4G'(P,AQ/'>/>AJIZ!USZ
M:'>'84^,86Y_I6>][SJ8C@1"'VWTCQ6@B\,9T:"^8YL(Q@<&E6D(SKEGX.5G
M,$;<F(?#DB<*_'SS]98R",F-O3'MTW:T5[#'5PE9@V2TF(MV#Z+XK[]&6$^5
M8\TPT8<NJS&ER[BB")E*L;&#[_[K+:ZM^^I0Q^ ZVJ+%S[I@4BQT8PT.0>NO
M?'2K6[ RF"'LR O7TIAXF^8@4V'3^Y8D;J])W%T4,WS?59$HM#+*(QK.U@IY
MP#RH-+1A8Q8X7"_!$2JNF)#8TF8<I<7]_=,DRSY]&EGO]UK T&WXG :G:K(+
MY%FY=E%C.#XS; R?8X<,W^.2(/4B9EM<UP]&>G!?ZU/>IXT@8L',@EN=!L1(
MTJ_M84P$[UKYH65,K]^??3#DR[[XI^>"S5/&T/,)<_P'A#]!T^"7JEPN%."]
MI_#NA&%Z7(OJ^U[ ,YDXU9/,QRZ5P>(,(Y=EX3K!VN;!KDJRLUZ[.\&"/3P\
M/$)^\*.'M&XT79V/E,<:0YH*E,Z3:JJE@<BQG+M;5G7'T,-'_O#HX=YX%.]-
MX/_F(XK^EK+[LG-GFG5_CP#0)3YMFO(^/7T<$.!8DP4_Y+$J/&"O93SH8@_/
M6.RKDM[!X7*6CG.F#+2H!ZQ  'F*<'RS4<[C[U'.FT4Y5:EU6DN&M!P*8-D
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MABY:STO-T'P9',A>.7)C4?1@L !DRI1$@D 7]6T"YN"<O_WOR7QQ$OV9-)]
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M!L9<IW8NU]Q2M\Q=9P>]FJGW:KKV-X$BD9^^OR>5;P]DEI8#6Q&5&-7*?(N
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M+G^R2KT36[3 /3K7"[H^;D:7E5_'!,,1E#87C&WPV4;Z/E+SKMM$@- K-*M
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M>&1FD24V<FAL(NWJ_+67G8NFW$//I0.#'6#\ VY4J[5LNYMS&RPB5$?(\&!
M.QWVD>[243D-=H78)WJB:3KNE"VMN7[RIVF&R1*FH6XWCJ!D WCN4]?@)::#
ME-3(98#*>I&L6#T1E(8*'Z==T@S9RCSA(%NXBS(.Y?E1&N38#3"]3/-R(:7H
MEV5^R2W(M(H)#V'WRP1\!^5*^@P^O_?9) )U:QQA!Q%Y: <*^%*2@=9 OO,B
M.1?]ZV6.)SBD"0@1CVRG[J8K$66F0:I,;A&I#G*ZQA$#Q^A,$[6A36]]P4WN
MP;DP-:!EK: *5BI(#5EGN9D)J<-VC%^C>&VF))L(<SGD_BX\L3"<(^)R.9]K
MT>LP_\;U)ND-(B>?8E>TNU0Z)W?7B/[:)2I#ND:JK\Z$??JOY?2<6_>4/E).
M5@VFYNI4DDR4<,O@W,XM&S(I&.K\J15B$B@VR*U6"R.16 -)^'%* !Z;P.IU
M1-1$1'&A<2@6Z$+N\,4K?0]FQU]D8],E5PNZG?SJ52V^N0)*-T=TV04 )D$3
M4-/1US ZXAI5R50PN 9'XCFSVYU$F!;"T<2AN= ".F1?/H(^_6+Y*F6[S:O\
MNU3^(30,3-QL.<?/&QZE<5)\(MGKB^Q=XR\0^6+^O4FG]!@8KYDS%2HQHEF9
M,TUA$RB>:KG0^?2\LK1DI\*4JKF(29XF'-@3 @FGE?\HR%RDM]<GR,YI,23E
MLJ%@"JF-&JTUU7L7X NA,"2Z-J=R.D_TMQ(7@;_M6 >"SU'/SD2"_S#P"M9Z
MLA(N89+$P<#XA)K&IZ%!29.N,J0]#Y4GNBVJID"WE3B%"7+OX@P-"ZX6;_8M
M$ZU&7J=45^JZMW@9ZB2G="VQ=#!.<EX:T7DYZDI-E(OUUQ>,NSLWE8S1+0G&
M;S%Z>?0]>GG;M#L?VZ 3HB$>/)3MY-]T"?I$:D[0^O['LFRD%V9+A]RY-LY'
MT9NSW]Z?!MFO)*NI*X').XL/A!8V.4>,7-#LI4W#+S4O2++7W4M+ GN")_..
M)SH/2^ULUZ:QQ# ,L-73:@9H) [UI5/3?@M]6!<?XT   6L&F&B1ON:NJ6@9
M_^=X<ENM'4(*.NVV)2UMG,\"H[5T=.5LRU@;Z(_[B*T5@[O=2L1?**.<.GDM
M=$VJZ!K^O 10W'7@**94#GA^#H."Q7Z@&SO1K8NYWG(CNOO8C7)P-WP86$M\
M'#M*)T \)&TM=-C1ZKH+&![WW9W>?KH.69B@"9=,G#VR ?8W@/"SX+Z!S))_
MI04;]W#K;D3IA<@\?#EA;*1UWE!:U[]?8 CA7:>,@+CQ>XFCEL6PXLB=4;DJ
M.EE]&Y]3?>S:'K"^$O%N#^1B%)T.@D7[;E$?-B2Q)\\9L!C);9*J31 6VQ4R
M:]/T<#8-+-:ZDKZOLT[/NN14A*W&Y\T+ZB$+VW=!+1F2:IZC=.N2-IPG6-[H
MXO08.P*'(YMCI&Z:S)-S=E[RC"-9%$AC4F#R'JE0D*"YAJO$OH E(<AU ^_M
M5%B:WAHPFG*64+<P;@ <#BKJ'Q/)88UL9877!*Z\IJ*8]9*\+?QL!?<YJ94M
MW;&$V/[G^+$<:7^F6U&(H#>3J/$PG-7[@I*_ ;^H0W_BHKL^P5BVVR R=7@+
MJ;>[T\?6@1\2$C%D#$+"H'6L80\>8-(LW-N]9. )H^#Q&0_%Y#CT19P"+:M^
M>J[M ++_S(1 @1"B<[GVG%(@PS!6Z?DL#=ZT5I)#5G?A*>4>C&8AZ=-3]W%,
MIMD6V&OH;3I4-8[?"_XZIWJ6KKS1%I\P;(YFM6INC6#-"@DI]A&/]A0[<14V
M*6$.8< )%5PKVQ:F]SD%N$"@.#'C!H +KF]>3RO:V\H;95*>=H/A:KE_;E)M
MMN0^@").!)S*-RO>5GPH:G,J0+WW":^H3W9A07OWCVL/D5"W_+,+L2T1Q[W7
M_RY+IDD?W8P#Y]NE)#T^_A[PNFTL>)NI(U9#+%])=4+#-AJS^FZP"1M+V+C&
M'APRO9SM9X7BMV+V]4O'_U_-OD!B[NX,\K3)Y]1FNW\1>HN6D7!'=$VCMHEY
MBY91T.8H, 6X;6Y9F.">_)YL!+H+USNAO;I]=\?]\HK"4]^X@K_&:;T/DI1;
MT/@G?>:TE; ;+&DT]'M-:?N,:UO1T?6-Z(/HM&;&?:T<]]'3=M06+-EV=WJ,
MX'L @O)BN.YW 5_56==_9.-\GB;2W4 DF$73!;%,NSI]?D=S45$A3E\8"J8/
M/]?25$!ZAZ \.,&D+"=-?;%]Y*B7G 33+L\H#>C-_<,<KZ)69PDFV,YJ7]9L
MR'.[-*OF=IH0;Z$<:/"(MM_VG+X'+T$!J%%%.&#X$CKEL^Q\25WI%XN4J2.T
M74XV:[!(JX*I)HN+-4U,3&9*=L\7,MM)6(7+H*H4^54OXJ@ D^>"OY,6]JWK
M>J=T7WOWH3RL^7I'E*YHP<V88'V29F#$TV8[^PU3(UC3N%*:,A\*]I%@Q >,
MM1$N;*:O5.5-G,\1!>'L&=>\(=9#UWH77R+N""(WOFMK^8Z[3-@N=B1OGAB?
M1)-.3]3!2R-EI9+ D0H;=L^7<+LU==DWF48KK<..7)(9S9=<*;_^'=Z91P&>
M7J:NQ0_)6N>2*XLWVKD4>/8';(%;-Y5'ZOEK1>5YHYXI +$G.B#TD%P3KW8*
M\96D?RVGL)]3;(CBA1'<CUF:89<VSFM(VO!26L'53I2#?!XYT2;KPLK&4Z$L
MJT8PP'>U?"S\>XYY"W3]1<M\ (J5;:^V"G/4$V-:R2;P?[H7@7&E?I9K5F+-
M 8W7KQ[2 1";8<XJ"?\&5M4BB.HAHW/_J>&'7%&/(7$"#7<)[6O?J[F!>;[B
M:64I/Y][XPD8B Z/GP0]5*N5C+'1SN$-")4][,'J5E*QN(:%L$47VGE"C/O6
M(LKISHP"S4B)05)51*'KV=6S$L,CEDP?$>G3X2DW+='&6^(CADTI$<KN>WN%
M9<O^LR0SRJ3$*Z-@]< Z;+DDOL2H+^[:L_(#G%FM!;#LL*:8GGE^$!%MC$V,
M<?U6#JY6V%6DVQ9]Z(AH$Z.+M(UO!&U;H5.$\C(6U'=MBJS@GY5KH.HP=BV+
ME3TB0Y]@& S:5K+7F93MU;(.&;+G*4?[QM4+")"@9NGD$\M[K>J7WNFC3D;[
MF:LT,?%<4H,+A-L'9[TU5$R@4&B(SYQ;MSA8-8,\]/S77"Y4<TS:@2*)\ 2\
MX3IUV.#N8!T\)PQ\T\*RU]_O? 3E--,R94YEQ_]O?&-.\M*%B)*I\Y*Q9]DR
MQ]DM\X4#[".4UNB]!"-8XY4@B[VEW*LHON%P[8/OX=K;)@\X:YUXEQ0<9IY3
M^Y#HV1)L#J'87:R:POHV1-!D(J[">&Z?'15MZ2T8NU[.]BT%8JE6T /WN#U&
M@\TO2 L-*DDG#%E#$@J(:/=<;91AWQO0GZTJMMN,+V?"%H(53V6EQ",9^<'P
MJRHCHPV[,,]RU4/<K^K2=2$..XH&"",):Q8@-B\X&#)MQXP<EHUUK;-L^ILH
M@B4\"W*9*4K<LGTB91RVMZ\WMZE_%55]LJ1=I!C1DII0$ZO)DZOK;['(>+_%
M!+/?O,?7W0ABA'1QENZ68%26:JF#'2,]T:D&=+L4;;E) ]93T ?$1VQK,17X
M!',<[1;/,&&?KK"9=%(;2Q'U]25"*ZCT3NRV DL4I>:.&0*_Y#"O72:^X\+6
MI][9%..%&I?/E$QUGK:V&W\MW:QMP][NG=AC703/)<)N0](X&AS_.$TJM0WY
M)0&6&HD*F0Z4R?_F;O?:#PRIF<0.W]UA_[2%]*.7<16'U.IBI3)IU2[_06M'
M^+":-420<U:T:[?)B"6J:[7683JU+Z_&=TB6X9J9,8G\;\C*".*J)QM#]>FX
MY#;Z1WF";//Q*GLX@8-+J.>/W.O459JZY<-J=31Y/Q7E%7CBY\@+.9E0PC0<
M$;UM@<<0BY=77'?)#85*QZ<FIK1)T_@+'G+S]]X+Z?JNK>.HPY7XCW\MA7_7
M7]1L%CH1G3;4U@Z8BAU K13"0P(W*(+;GE@=L9=2X7D/&2@]H"'WA^&U1<I=
M&5:.@61W1XCZJ,A:XMB"2(735DX%5*LO8\'G;/J&F%:9^=_5HP^(I\#B<,9-
MS^QY]8>-BEYSJJ<P?E@:[^Y\J:6T;MR6[3<0D;[SV9?!K'J5ZQ>DB79W6JX:
M.O@-?AM#DPY8'P+\>R:*8>$@!^/F;!.VQHK@W"+M)TK7SQ-3_R*_A[EZS )+
M<VXDG#3F#[9;A(8<M(G?-.ATHVAQJJ/;W:&K0-JF_3<A9:[M8,32U@,S *3%
M:+ /A@JCHY\_,BJ/%9CLS-QM!/=Z,!A%9:3WT/DRRSD.-JN2)3;F009/^&"K
MZ]F>(1K%U)N8H6%!S1%2(GE"SI'?5AO\#.28"R3+>#"">"4]E/S8I#6K#C#J
MC(]OO)5=*OPMB'_=K4.M90]<Y7NF9(4U2GCOB=W9T2H$9H-]8P#=N8<D5#H:
M(GU6W41#%Q:EEJ?J=@^CTU,E.RY;<?]^H) _UI0+H)JE"^Y0 %=N&EL&_;DM
M)_55M[%K28@%I>6*^%JXRB2HL.I+;K+VQ%_RN>),5T$4,W("R[QF$*G]6O\I
ME_/L'SJNRD]IM<\=2;PL3F9(K&O(I,RC?8NK30S<ABSBAAMB3FCP!M@@FX6Y
MA1T:VA=[+%K=4OR%E[S#!9=I<Z";XK;$)%$D\TU +-+=8XHDEPI12X;&,>*N
M#SKRM>?##G_MT?B&HX,/OT<';U/D'AUR#<]91P+(]0*KBKRXK&@5F47,!$V=
M7ZRM(EF%!@-&M:D_=)_U*01BR]NNP J%M+M4P9]4<WJ>?JTE=@2&[8=1_%UZ
M&G)>346BN&+!>$F;A[U+6+IX& B'$RFTQ>G#; N((GP*W@T[]5DQ7!<E=6"F
M/"&]51>_B[?I7Z5IR;U=6_-W4U';1#EZ*#9FI4:O!92X=+QPM,-CMBAA&9J?
MK(_(?>:"6%*SW[5;L@5+W[IMHQ]IWR@73X[;I6:M8RLNC1HR9/0\=5ZS;D6>
MR<0[?B6%+K0_R\QXI>[2=/,VE6WR/<J/USU/=V]=?<%K!JZ*>;4V$&; Q(4@
M.VC9R[I9H+_=7X-+J6)S? B>2HTC,#-;DT<_!;$K!%]2N"JITRN8$]JV0H?"
MPH"\U?'*P7V"WMAK=&\_&%2J9=JMK]!SML0$'@[6[AY?4CV8=,7.5R&ZM [A
MI;4_OML-T65JF6Y%:;#7+@.[&,0JT 4JFB*Z?ERD;K3UY,4"(F /-J,D5ZYM
M^VG7IT^.(P"#X'+0Y D7"48X,M!CA"=B3D"?#]Z T#1'=FU7FJ_DHHQ'E,!@
M(7V>$8.0IOC9M+4'IO?2&65),4N1\EG8ZP^/06 &<[BQ*WLZ1S)LE=27<:.H
MCB1?M!E35"SGX[1J2047^9\C*@DV7"<R]4$QZ?*T4>&!>-C'F#XB(U4E:%"D
M9Q34S.C"$*L@[4_DWS]4\#^HUKI22\(7;%IO'']1%OM^KW0& 3:W91*9);6K
MV8FL;+"2!)?3D:H$*S+.5?RUYX06H O)TI2B/:Z $,/(3_C#%T]88S*NT9^>
MR"WO"5XY\]K@.M(1X+!URE6&)Y1H0],#GRO@-CXO"B <O*$4#?*>+&71FUH_
M?1_2:7*?THFH,E@8F7*N.Y)&&M7\ZE(H6B>$+-$UGH99CQABD2D<MEX<!<2P
M=IG&=IGL#;_YY0XMYNOONA.U2%P44-+$O7PX'Y"M;CK@\FT*--FA4L8K7%PT
M#5+9K-\7@OGB*6EDEXPECA-1CBG!_O6*ZO/WN P[]WB:];7NSF9)&MK2COM5
M+Z%+C? 9&Y=5T6%\Z4_-K6EK^D3IB7P= ^56!$H<!+<=3U7=><PS\.8%VOYU
MQ>5=AIN/CC1?[1P^71TD&0'3WRU(W&;ZB:_;W4_7OZ^S>=R3=0]LX-(3,+?1
M?PVUD/13P(+;3K;5L/CJ7J$$)8ZN94Z='IC)=W='B991$%;37!)7C#$T4%E.
M(E(#VA#;*!XT,22[C.+0X-LA)WFF!#2IZ9OX#-T/M]UB5X6GP5U,";J8:C7P
MT";H$>*CRMAREVC0#0$E52@P,;:[M-81^2;CJ8^^QU-O5:8<'S#:,KB_+JSF
M],YTN$O@T6'0NK85>A&H-=XB<;];=2UEYU;UM]#5AKFJ)_!T/XN,E*<D@V+\
M%9*5U-QP=Z76@C8W]L2(_4*JUSTU,,R002HH. UR7BA5A@L@9YP_OH7Z<# )
M]LO9_J*<?$J;5JVMKS)%:-\EKZ?F4_MY]BQ]^L:FR_':TMEVD_%Y0E3*S/ C
M]E/;L-_8FIWVL"[]-G)9>-=Z#<]>4;K8\ V.8"2G3XV,>S %'E!4F!,>">J(
MH+4P=2FDZ1.JK%.GVF.N^E"A!K"E>V9?B)V *E+1"CLN!=M&N<9*\A:[6LK*
M\(JN5:JD?,M*&G:HG]87/08]=IK;YBONM;6^M_9%P^)1NSB%3??*9>!%0"^H
MARR5/D\Q'2\[,$Z:,CH&#!2D=0-7[3/^>I9,J$),>@@83H7AZ8!W]CSZI<RG
ML,?1!]BHH/?5R_(@>OOV91P='QY&?V(?F@\-3*OQ79A,/Z:CP^.GQ_O'1\^>
MQM%I0S4L9?$\C."^P@O8\':]31'G^2EZ![\I<+;TIJ,'AT?1*6S#TI>AG,[A
MDY,$5O@1V'YO\A*=I^X(X,N'AT?/@K=_:);HH[P_B'X#LR213NBO82DG&%O_
M!>3D(GI[\/;@Y0$\_5'T.H%)/CK&;NG=F?X=7_#H4?""UR__%OTB]/$O63:=
M1"^2:I*#2H]>2K^/LV("SW_R\!%<:'*K98I]T]C=Z9G&JI@R26*PG'NSY//S
MS9)\[_'#Q^(A/WWP</_IT8,'HQ/7YRHX?ITLU\T.'H4,IM/*@+O<&UH0VJ&>
MN^$Z*#?D,.N7IG\F6J]J+_J@1?$,XT)!9^,;S[T;T6O(F=/U< M K3?P+WUH
MI_^%L@6>6"38=(D,>GHU BHHQT!H?WQ5ZY,<!]*7D<E W=L%F=NE44 A06+5
MD66>:B'N>G%GY:SR?!(*5,)J\E NE6^L_KK3R-]9MP\X>V(4*@H\TC\^G()8
M K<?-#XQ)'Y$-12=G9WA)]XMQR 6#[:@DSY\LO_HL5ZTO1HL;M+JJ,WRY"KZ
M'1ROL?9O/'Y,8O9H-(I[XA=5"*1DPNTX@M.I?%&PP#"W /3,4&1<+9<,#5%N
MDSSC30T;USAGK]O5BD$&G/&B:#8BB;C[B[WE Z]):H1=<A6#5EFTADL'E2@K
M^L-;U+4(33Z>UFKP;?=@(3W$8$FO5P,Z/&,T+5X&T?D%IO3K,D\]KY 4:$3J
MV70BB398TBXN[[4;G]&[CHX"A\E1.Z_C-6\C[H:!5.( !9$',>VR*FB9AK^H
M8R&!+\D$G(*WQV*??B9&[[HN97!)C;=&3$6DTU>01>V( 9()QWH1:<:XMY7$
MB]GH8A#[958URQYR<(;.B@]0J7$8&OX.TMH+<!90=^*'SDEQ&KF!^X(1@SNM
MX7I]YSV<TT<''%]V4U"8?EUKZY7V(BD]D'5';>9<^XHA'_&JA]>'L=,(9?1Y
M1]&5KEL/GTH\O7\FQ C?X%5Y!:89H@;AWG,]O;[J'A;N<:L*9.+J3FK&("K6
M 269J[<.TD?]O<#6Q".E/GRCLDFJN:[D?I["XKG4C6DJ9)J+P;XW5VF8!8[;
M%3K>1>L/R@:E8+$I\0ZK$4CI"[]%V#: 8/]"P>:,)CO*#@X8EX/+P41T4IG'
M EP)I-_('4";LU42&IYETR4L0 ^GN.D#U:I@(&P>\48PP14VYT%@%5YN_SP4
M;EC3(HX]AHN3RRY4MB_5XRK=@A8[@E;1Z$1[B<1%WLLJ(U:)J8 KP7I+$FCL
M;,;"\G&+)8+@X.];6A^/0, _/Q+Y+@#C%K[1?E.)<EJ9*D^YM2Z SQ0!MAF4
MZPF0U-PDCPLKT4R[*J1J!K_E^Q/*'M4MQ9@U3DC[0M/65387-Q,KA!J68DT,
MGG%!JK6.?V6TQ3RFD<+23KGADAX8UYM+E$N1, .0LUKH0>#$X$$V)[52PI=H
MNFQ6K<7NI??HW)[UI^@;CLD__AZ3OU7-]J1KNB[1RDJ))R3/I1V&\?/PY@E1
M'A>*U9[OQ/4XQP)*T!JC/F73FZGMWJD^R2ELM2*AHGL+B3Z%=[[X^6-/AV\4
ME_8B!B*>HM3]V0]N<JS\@5-V\ZLE&_5][BOXD<YPYUZ#\(.+R6GFGE.5[$"1
MHLQ3B:87LSQC(@EZ$OM@5+HJE9."%17.@";SF496!^C($D151^/"=IWA#(M<
M+D?,I!BWU)X^2BT3,EYT,[\$;MA^M348 @X^PV)R,"DQ+ZR3_>/@PT'T*N.V
MQQC6JTPZ$]83YEWXO_,,I4<1AB8)TY(TTKK:@0"EWW=P=/]:PA2GV<11DKJ8
MMGR;RFQY^VGQ%): L48NI7.;/0R\A9?.,W=[[#O)TY3J&8I(1IE2#-+[ZX.?
M?GSQ\]T':XZ>=0NNA_((:C*A27193B@C=)5P2LEUF<IS#%^KI[R.#4-?1R
M]"/A)I=X5K I)[),,8#:5^[V'%C/@,REZFS<=@\NN5&##7]Y7G<OUXX/61M8
MP))P7+GV;5H77I A0T!UV9I6,D>6RL/%J#(\K?!C& J0314X8B^91%(X,'0L
MI!^Y.Z/N61IY+,]9";D(*;LSSI'!B%5&4I5=VSL_V\<"JKD"85ZK \T+BU)
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MW<C:"(#1?Q09=4,TS_YH3XXKRKS;RWI\0',Z+S*U?9R%\ $[ ,-RO4_K,F>
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M'" &1^WKV;_APT]W7SX?_S]02P,$%     @ B8I:7)Q+V0SG"@  8"    \
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M"VX]=@'7.[4_\I'9=ER[V_6JN[]L_0*W._V+WFPU@X8^?P%02P,$%     @
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M47'B(T,'0E27X(NV'<C_82OD,MHKS1T>L$^[KL_8?_;933SR#U!+ 0(4 Q0
M   ( (F*6EP.N0<=.A(  $-Q   -              "  0    !D.#4S,SAD
M.&LN:'1M4$L! A0#%     @ B8I:7*&/L(*XE0  >@X#  \
M ( !91(  &0X-3,S.&1E>#$Q+FAT;5!+ 0(4 Q0    ( (F*6ER<2]D,YPH
M & @   /              "  4JH  !D.#4S,SAD97@U,2YH=&U02P$"% ,4
M    " ")BEI<I(R'FSH#   Y"P  $               @ %>LP  =FER+3(P
M,C8P,C(U+GAS9%!+ 0(4 Q0    ( (F*6EQK<%GM>P8  +A&   4
M      "  <:V  !V:7(M,C R-C R,C5?;&%B+GAM;%!+ 0(4 Q0    ( (F*
M6ES)+4]SO00  #,L   4              "  7.]  !V:7(M,C R-C R,C5?
=<')E+GAM;%!+!08     !@ & '<!  !BP@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>d85338d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vir-20260225.xsd" xlink:type="simple"/>
    <context id="duration_2026-02-25_to_2026-02-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <startDate>2026-02-25</startDate>
            <endDate>2026-02-25</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-288">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2026-02-25_to_2026-02-25"
      id="Hidden_dei_EntityCentralIndexKey">0001706431</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-299">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-300">2026-02-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-301">Vir Biotechnology, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-302">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-303">001-39083</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-304">81-2730369</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-305">1800 Owens Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-306">Suite 900</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-307">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-308">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-309">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-310">(415)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-311">906-4324</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-312">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-313">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-314">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-315">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-316">Common stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-317">VIR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-318">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2026-02-25_to_2026-02-25" id="ixv-319">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
